, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 1 
08 JUN 2020 Phase 2/3 Study of A rimoclomol in Inclusion Body Myositis ( IBM) 
A Randomized, D ouble- blind, P lacebo- Controlled Trial 
Protocol Identifying Number: IBM4809 
Version Number and Date:  9.0 , 08 June 2020 
IND Number: 076773 
EudraCT Number: 2017-004903-33  
Study Registry ID: [REMOVED]
IND Sponsor: Orphazy
me A/S  
Ole Maaløes Vej 3 
DK-2200 Copenhagen N  
Denmark   
International Coordinating , MD, Professor of Neurology 
Investigator:  University of Kansas Medical Center (KUMC)  
3901 Rainbow Boulevard, Mailstop 2012 
Kansas City, Kansas 66160 , U.S.A.  
International Coordinating University of Kansas Medical Center Research 
Investigator Institution:   Institute, Inc. 
International Coordinating , MD, Professor in Clinical Neurology  
Co-Investigator:    
International Coordinating  University College of London (UCL) Institute of  
Co-Investigator Institution:  Neurology, London, United Kingdom   
Study Drug Name:  Arimoclomol  
Development Phase:  2/3 
Date of Protocol:  08 Jun 2020 
Date of previous protocol:  24 JUL 2019 
This document contains information which is the property of KemPharm Denmark 
A/S and is provided here as part of the results registration on clinicaltrials.gov. It 
is understood that this information cannot and will not be disclosed to others 
without written approval from KemPharm Denmark A/S.
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 2 
08 JU
N 2020 Confidentiality Statement  
The information contained within this document is confidential and has been developed by 
Orphazyme A/S, UCL (  and ), and KUMC  (  and 
). This material should only be used in connection with the conduct of the 
study or  matters authorized by  Orphazyme A/S, UCL or  KUMC . The information should not 
be disclosed to others without prior written authorization of UCL’s or KUMC’s researchers or 
Orphazyme A/S’s representative . 
CONFIDENTIAL
CONFIDENTIAL
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 4 
08 JU
N 2020 TABLE OF CONTENTS 
SIGNATURE PAGE  ........................................................................................................ 3  
TABLE OF CONTENTS .................................................................................................. 4  
LIST OF ABBREVIATIONS ........................................................................................... 10 
INTERNATIONAL COORDINATING INVESTIGATORS’ AUTHORIZATION ................ 13 
SITE PRINCIPAL INVESTIGATOR’S AUTHORIZATION ............................................. 14 
1 PROTOCOL SYNOPSIS ........................................................................................ 15 
2 KEY ROLES ........................................................................................................... 23 
3 INTRODUCTION: BACKGROUND INFORMATION AND SCIENTIFIC 
RATIONALE ........................................................................................................... 24 
3.1 Background Information ................................................................................ 24 
3.1.1  Name and Description of the Investigational Product  ......................... 24 
3.1.2  Summary of Findings from Nonclinical In Vitro or In Vivo Studies That Have Potential Clinical Significance  ........................................... 25
 
3.1.2.1  In Vitro Cell Model of IBM  ..................................................... 25 
3.1.2.2  In Vivo Model of IBM  ............................................................ 27 
3.1.3  Summary of Human Clinical Pilot Research Data .............................. 28 
3.1.4  Discussion of Important Literature and Data that are Relevant to the Trial and that Provide Background for the Trial  .................................. 29
 
3.1.4.1  Pathology  ............................................................................. 31 
3.1.4.2  Protein Misfolding  ................................................................. 32 
3.1.4.3  Primary Endpoint: IBMFRS  .................................................. 33 
3.1.5  Importance of the Study and Any Relevant Treatment Issues or 
Controversies  ..................................................................................... 33 
3.1.5.1  Rationale  .............................................................................. 34 
3.1.6  Potential Risks and Benefits  ............................................................... 37 
3.1.6.1  Safety and Tolerability  .......................................................... 37 
3.1.6.2  Known Potential Benefits  ...................................................... 38 
4 TRIAL OBJECTIVES AND PURPOSE  ................................................................... 39 
4.1 Objectives  ..................................................................................................... 39 
4.1.1  Primary Objective  ............................................................................... 39 
4.1.2  Safety Objective ................................................................................. 39 
4.2 Estimands  ..................................................................................................... 39 
4.2.1  Primary Estimand  ............................................................................... 39 
4.2.2  Secondary Estimand  .......................................................................... 39 
5 OVERALL STUDY DESIGN ................................................................................... 41 
5.1 Description of the Study Design  .................................................................... 41 
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 5 
08 JUN 2020 5.2 Study Endpoints  ............................................................................................ 41 
5.2.1  Primary Endpoint  ................................................................................ 41 
5.2.2  Secondary Endpoints  ......................................................................... 41 
5.2.2.1  Six Minute Walk Test  ............................................................ 42 
5.2.2.2  Modified Time Up and Go  ..................................................... 42 
5.2.2.3  Muscle Strength Testing ....................................................... 42 
5.2.2.4  Health Assessment Questionnaire ....................................... 43 
5.2.2.5  Number of Falls and Near Falls  ............................................ 43 
5.2.2.6  SF-36 .................................................................................... 43 
5.2.2.7  Patient Global Impression of Severity and Change  .............. 43 
5.2.2.8  Clinician Global Impression of Severity and Change  ............ 43 
5.2.2.9  Safety Endpoints  .................................................................. 43 
5.2.2.10   ............................................................. 44 
5.2.2.11  Pharmacokinetics Assessments  ........................................... 44 
5.2.2.12  Biobanking  ............................................................................ 44 
6 STUDY ENROLLMENT AND WITHDRAWAL  ........................................................ 45 
6.1 Trial Conduct  ................................................................................................. 45 
6.2 Inclusion Criteria ........................................................................................... 45 
6.3 Exclusion Criteria  .......................................................................................... 45 
6.4 Strategies for Recruitment and Retention  ..................................................... 46 
6.5 Participant Withdrawal or Termination .......................................................... 47 
6.5.1  Reasons for Withdrawal or Termination  ............................................. 47 
6.5.2  Handling of Participant Withdrawals or Discontinuation of Study 
Treatment  ........................................................................................... 47 
6.5.2.1  Premature Termination of the Study  ..................................... 48 
6.5.2.2  Premature Discontinuation of Study Participation at 
Individual Centres  ......................................................................... 49 
6.5.2.3  Regular Termination of Study  ............................................... 49 
7 STUDY TREATMENT  ............................................................................................. 50 
7.1 Study Agent(s) and Control Description  ........................................................ 50 
7.2 IMP Manufacturing ........................................................................................ 50 
7.3 Formulation, Appearance, and Packaging  .................................................... 50 
7.4 Product Storage and Stability  ........................................................................ 51 
7.5 Preparation .................................................................................................... 51 
7.6 Dosing Route and Regimen  .......................................................................... 51 
7.7 Starting Dosage, IMP interuption, rechallenge and permanent 
discontinuation ............................................................................................. 51 
7.8 Duration of Therapy  ...................................................................................... 52 
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 6 
08 JU
N 2020 7.9 Investigational Product Accountability  ........................................................... 52 
8 STUDY PROCEDURES AND SCHEDULE  ............................................................ 53 
8.1 Study Specific Procedures  ............................................................................ 53 
8.1.1  Consent  .............................................................................................. 53 
8.1.2  Inclusion/Exclusion/Eligibility/Screen Failure  ...................................... 53 
8.1.3  Medical History Including IBM history  ................................................. 53 
8.1.4  Physical Examination  ......................................................................... 53 
8.1.5  IBM Functional Rating Scale  .............................................................. 54 
8.1.6  Patient Global Impressions of Severity and Change  .......................... 54 
8.1.7  Clinician Global Impressions of Severity and Change  ........................ 54 
8.1.8  Muscle Strength Testing ..................................................................... 54 
8.1.9  Modified Timed Up and Go (mTUG)  ................................................... 54 
8.1.10  6 Minute Walk Test with 2 Minute Distance Captured ........................ 55 
8.1.11  Falls Diary  .......................................................................................... 55 
8.1.12  Health Assessment Questionnaire – Disability Index (HAQ - DI) ........ 55 
8.1.13  Columbia Suicide Severity Rating Scale  ............................................ 55 
8.1.14  Vital Signs  .......................................................................................... 55 
8.1.15  ECG  55 
8.1.16  SF-36 .................................................................................................. 55 
8.1.17   ............................................................................................ 55 
8.1.18  Biobanking  .......................................................................................... 56 
8.1.19  POP PK  .............................................................................................. 56 
8.1.20  Laboratory Pr ocedures/Evaluations  ................................................... 56 
8.1.20.1  Specimen Preparation, Handling and Shipment  ................... 56 
8.2 Study Schedule  ............................................................................................. 57 
8.2.1  Screening (30 Day Window) (Visit 1)  .................................................. 57 
8.2.1.1  Randomization ...................................................................... 57 
8.2.2  Baseline (Visit 2, Day 1)  ..................................................................... 58 
8.2.3  Ongoing Treatment Visits (Visits 3 to 13, Months 1 to 18)  .................. 58 
8.2.3.1  Months 1 and 2 ..................................................................... 58 
8.2.3.2  Months 3, 5, and 6 ................................................................ 59 
8.2.3.3  Months 4, 8, 12, and 16 ........................................................ 59 
8.2.3.4  Months 10, 14, and 18 .......................................................... 60 
8.2.4  Final In- person Study Visit and Follow -Up Phone Call  ....................... 60 
8.2.5  Early Termination Visit  ........................................................................ 61 
8.2.6  Unscheduled Visits  ............................................................................. 61 
8.2.7  Exceptional Circumstances Preventing Patient From Attending In-
Perso n Visits  ...................................................................................... 61 
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 7 
08 JU
N 2020 8.3 Concomitant Medications, Treatments, and Procedures  ............................... 63 
8.4 Precautionary Medications, Treatments, and Procedures  ............................. 63 
8.4.1  Prohibited Medications, Treatments, and Procedures  ........................ 63 
8.4.2  Prophylactic Medications, Treatments, and Procedures  ..................... 64 
8.4.3  Rescue Medications, Treatments, and Procedures  ............................ 64 
8.4.4  Participant Access to Study Drug At Study Cl osure  ........................... 64 
9 ASSESSMENT OF SAFETY  .................................................................................. 65 
9.1 Adverse Events  ............................................................................................. 65 
9.1.1  Adverse Event Definition .................................................................... 65 
9.1.2  Definition of a Serious Adverse Event  ................................................ 65 
9.2 Recording and Reporting of Adverse Events  ................................................ 66 
9.2.1  Definition of Severity of Adverse Events  ............................................. 67 
9.2.2  Definition of Relationship of AEs to a Medicinal Product and/or 
Study Procedure  ................................................................................. 67 
9.2.3  SAE Reporting Procedure for Site Investigators  ................................. 68 
9.2.4  Follow- up SAE Reports  ...................................................................... 69 
9.3 Reporting Serious Adverse Events to the IEC/IRB  ........................................ 69 
9.4 Reporting of Suspected Unexpected Serious Adverse Reactions (SUSARs)  69 
9.5 Adverse Event Reporting Period  ................................................................... 70 
9.6 Follow- up for specific laboratory abnormalities  ............................................. 70 
9.6.1  Increased serum creatinine  ................................................................ 70 
9.6.2  Increased transaminases  ................................................................... 70 
9.7 Study Halting Rules  ....................................................................................... 72 
9.8 Study Discontinuation  ................................................................................... 72 
9.9 Safety Oversight  ............................................................................................ 72  
9.10  Data Monitoring Committee ........................................................................... 72 
10 CLINICAL MONITORING  ....................................................................................... 73 
11 STATISTICAL CONSIDERATIONS  ........................................................................ 74 
11.1  General Considerations  ................................................................................ 74 
11.2  Statistical Hypotheses  ................................................................................... 74 
11.3  Analysis Populations  ..................................................................................... 74 
11.4  Description of Statistical Methods  ................................................................. 74 
11.4.1  Baseline Descriptive Statistics  ............................................................ 74 
11.4.2  Analysis of the Primary Efficacy Endpoint(s)  ...................................... 74 
11.4.3  Analysis of the Secondary Endpoint(s)  ............................................... 76 
11.5  Safety Analyses  ............................................................................................ 76 
11.6  Adherence and Retention Analyses  .............................................................. 76 
11.7  Planned Analyses  ......................................................................................... 76 
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 8 
08 JU
N 2020 11.7.1  Safety Review  .................................................................................... 76 
11.7.2  Additional Sub -Group Analyses  .......................................................... 76 
11.7.3  Sensitivity Analyses  ............................................................................ 76 
11.8  Sample Size Considerations  ......................................................................... 77 
11.9  Measures to Minimize Bias  ........................................................................... 77 
11.9.1  Breaking the Study Blind/Participant Code  ......................................... 77 
11.9.2  Unblinding for Data Monitoring Committee  ......................................... 77 
12 SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS ....... 78 
13 QUALITY ASSURANCE AND QUALITY CONTROL  .............................................. 79 
13.1  Quality Control  .............................................................................................. 79 
13.2  Quality  Assurance ......................................................................................... 79 
13.3  Audit  .............................................................................................................. 79 
14 ETHICS/PROTECTION OF HUMAN SUBJECTS  .................................................. 80 
14.1  Institutional Review Board ............................................................................. 80 
14.2  Regulatory Body Approval ............................................................................. 80 
14.3  Informed Consent and Screening Data ......................................................... 81 
14.3.1  Confidentiality  ..................................................................................... 81 
14.3.2  Staff Information and Responsibilities  ................................................ 82 
14.3.3  Essential Document Retention  ........................................................... 82 
14.4  Data Handling and Record Keeping .............................................................. 83 
14.4.1  Data Collection and Management Responsibilities  ............................ 83 
14.4.2  Protocol Adherence  ............................................................................ 83 
14.4.3  Data Storage and Backup .................................................................. 84 
14.4.4  Study Records Retention .................................................................... 84 
14.4.5  Protocol Deviations  ............................................................................. 84 
14.4.6  Publication and Data Sharing Policy ................................................... 85 
15 STUDY ADMINISTRATION .................................................................................... 86 
15.1  Study Leadership  .......................................................................................... 86 
16 CONFLICT OF INTEREST POLICY  ....................................................................... 87 
17 CORONAVIRUS (COVID) OPERATIONAL CHANGES  ......................................... 88 
18 LITERATURE REFERENCES  ................................................................................ 89 
APPENDIX 1: EUROPEAN NEUROMUSCULAR CENTRE INCLUSION ..................... 94 
APPENDIX 2: IBM FUNCTIONAL RATING SCALE  ...................................................... 95 
APPENDIX 3:  SUB- STUDY  ................................................................................... 96 
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 9 
08 JU
N 2020 List
 of Tables 
Table 1: Retrospective chart review of IBM from 2000 to 2010 at KUMC  ..................... 30 
Table 2: Schedule of Event s ......................................................................................... 62 
List
 of Figures 
Figure 1. Arimoclomol amplifies cell signal to make molecular chaperones  .................. 25 
Figure 2. Over -expression of β -APP and exposure to inflammatory mediators induces 
IBM like pathology in cultured myocytes which is ameliorated by treatment with 
arimoclomol  ........................................................................................................ 26 
Figure 3. Treatment with arimoclomol prevents the loss in muscle force and 
appearance of IBM -like pathology in mutant VCP mice  ...................................... 28 
Figure 4. Proposed pathogenic cascade of sIBM35 ....................................................... 32 
Figure 5. Schematic of the mechanism of action of HSP7040 ........................................ 33 
Figure 6. Arimoclomol -induced increase in HSP70 and HSP90 in SOD1 mice42 .......... 34 
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 10 
08 JU
N 2020 LIST OF ABBREVIATIONS 
Abbreviation  Description  
Ab antibody  
AB-42 amyloid beta -42 
AE adverse event  
ALS amyotrophic lateral sclerosis  
ALSFRS  Amyotrophic Lateral Sclerosis Functional Rating Scale  
ALT alanine aminotransferase (SGPT)  
API active pharmaceutical ingredient  
AST aspartate aminotransferase (SGOT)  
β-APP beta amyloid precursor protein  
BiP binding immunoglobulin protein  
BUN  blood urea nitrogen  
CE clinical evaluator  
CGIC  Clinician Global Impression of Change  
CGIS  Clinician Global Impression of Severity  
CHOP  C enhancer -binding protein homologous protein  
CIOMS  Council for International Organizations of Medical Sciences  
CRF case report form  
CRO  contract research organization  
C-SSRS Columbia Suicide Severity Rating Scale  
DILI Drug -induced liver injury  
DMC  data monitoring committee  
DNA  deoxyribonucleic acid  
ECG  electrocardiogram 
EDL extensor digitorum longus  
EMA  European Medicines Agency  
ER endoplasmic reticulum  
FDA Food and Drug Administration 
FF finger flexor  
GCP Good Clinical Practice  
GFR  glomerular filtration rate 
GGT  gamma -glutamyl transferase  
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 11 
08 JU
N 2020 Abbreviation  Description  
H&E histopathological  
HAQ -DI Health Assessment Questionnaire – Disability Index  
HDPE  high density polyethylene  
HERG  human ether -a-go-go-related gene 
HIV human immunodeficiency virus  
HRQoL  Health Related Quality of Life 
HSF-1 heat shock factor -1 
HSP heat shock protein  
HSR  heat shock response  
IB investigator’s brochure 
IBM inclusion body myositis  
IBMFRS  IBM Functional Rating Scale  
IBMPFD  inclusion body myopathy with Pagets’ disease and frontotemporal 
dementia  
ICH International Conference on Harmonisation 
ID identification  
IEC independent ethics committee  
IMP investigational medicinal product  
IMPD  investigational medicinal product  dossier  
INR International Normalised Ratio  
IRB institutional review board 
ITT intent ion-to-treat 
IUD intrauterine device  
IUS intrauterine system  
IVIg intravenous immunoglobulin  
KUMC  University of Kansas Medical Center  
LDH lactate dehydrogenase  
MAR missing at random  
MCV mean corpuscular volume 
MMT  Manual Muscle Testing  
MMRM  mixed model repeated measures  
MSG  Muscle Study Group 
mTUG  Modified Timed Up and Go  
mVCP  mutant valosin -containing protein  
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 12 
08 JU
N 2020 Abbreviation  Description  
MVICT  Maximal Voluntary Isometric Contraction Testing  
NASH  Non-Alcoholic Steatohepatitis  
NFkB  nuclear factor kappa-B 
NOAEL  no-observed- adverse- effect -level 
OPD  Orphan Products Development  
p62 nucleoporin protein p62 
PGIC  Patient Global Impression of Change  
PGIS  Patient Global Impression of Severity  
PI principal investigator  
PIB Pittsburgh Compound B  
PK/PD  Pharmacokinetic/Pharmacodynamic  
PO by mouth  
POP PK  population pharmacokinetics 
p-Tau tau protein 
QA quality assurance  
QC quality control  
RBC  red blood cells  
RNA  ribonucleic acid  
SAE serious adverse event  
SAP statistical analysis plan  
SF-36 36-Item Short Form Health Survey
sIBM  sporadic inclusion body myositis  
SOD1  superoxide dismutase 1 
SUSAR  suspected unexpected serious adverse reaction 
SMR  standard mortality ratio  
TA tibialis anterior  
TBL Total Bilirubin  
TDP-43 transactive response DNA binding protein 43  
t.i.d. three times a day 
UCL University College of London 
ULN upper limit of normal  
VCP valosin -containing protein 
WBC  white blood cells  
wt-VCP wild-type human valosin- containing protein 
CONFIDENTIAL
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 14 
08 JU
N 2020 SITE PRINCIPAL INVESTIGATOR’S AUTHORI ZATION  
I hav
e read the Phase 2/3 Study of Arimoclomol in IBM  protocol  dated 08 Jun 2020  
(Version 9.0), and agree to abide by all provisions set forth therein. I agree to comply with 
the International Conference on Harmonisation Guideline for Good Clinical Practice 
(ICH-GCP), national and local regulations and the Declaration of Helsinki.  
The amendm
ents contained in this version of the Clinical Trial Protocol are intended to 
be implemented immediately by all investigators as either an Urgent Safety Measure as defined by the EU clinical trials directive or as permitted in other regions. This may mean that the implementation of the amendment is prior to approval by competent authority or IRB/IEC.  
SIGNATURE:  DATE:  
......................................................................... .................................. 
Pr
int name:  
......................................................................... 
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 15 
08 JU
N 2020 1 PROTOCOL SYNOPSIS 
Title:  Phase 2/3 Study of Arimoclomol in IBM  
Protocol Number  IBM4809 
Type of Study  Phase 2/3 
Indication  Treatment of sporadic Inclusion Body Myositis ( sIBM)  
Principal 
Investigator  , MD  
Number of Study 
Centers  Approximately 12 
Study Duration This study is co-funded by a 4- year FDA Orphan Products 
Development  (OPD) grant  and Orphazyme. We anticipate  
approximately 15 months of active screening and enrollment, and 21 months of treatment and follow -up. 
Participant Duration  Each participant ’s duration will be approximately a total of 22 
months.  
Population:  It is intended to randomize approximately 150 patients with the 
aim of achieving 75 evaluable patients in each of the two 
groups ( arimoclomol and p lacebo).   
Study Design The clinical study will be a randomized, double- blind, 
placebo- controlled study in 150 patients with sporadic IBM 
followed for  a 20 month treatment period. In this study there will 
be two treatment groups of 75 patients each, i.e., 75 patients 
receiving arimoclomol 400 mg three times a day ( t.i.d) and the 
remaining 75 patients receiving placebo.  
Efficacy outcomes, safety laboratory  tests,  and adverse events 
will be collected. The long- term goal is to find an effective 
treatment for patients  with sporadic IBM. 
A data monitoring committee (DMC) will monitor  safety and 
tolerability during the trial according to the DMC charter.  
Upon completion of this study, qualified patients may enter an open- label extension study at their last treatment visit (Month 
20). 
Objec tives Primary Objective 
•To evaluate the efficacy of a rimoclomol at a daily
dosage of 1200 mg (400 mg t.i.d) compared to placeboin the treatment of sporadic IBM  at 20 months .
•
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 16 
08 JU
N 2020 Title:  Phase 2/3 Study of Arimoclomol in IBM  
Safety Objective  
•To evaluate the safety and tolerability of arimoclomol at
a daily dos age of 1200 mg (400 mg t.i.d.) compared to
placebo in the treatment of s poradic IBM over
20 months.
Primary and 
Secondary Endpoint s Primary efficacy endpoint is the change from baseline to 
Mont h 20 in the IBM  Functional Rating Sc ale (IBMFRS) total 
score.  
Secondary efficacy endpoint s will include  changes from 
baseline  to Months 12 and 20 in the following measures of 
strength and function:  
•IBMFRS total score (12 months)    6 minute walk test with
2 minute distance captured
•Modified Timed Up and Go (mTUG)
•Muscle Strength Testing
oManual Muscle Testing (MMT)
oIsometric Contraction Testing of bilateral
quadriceps strength using the MicroFET
•Health Assessment Questionnaire (HAQ -DI)
•Grip strength using the Jamar device
•SF-36
•Falls  and near  falls
•Patient Global Impression of Severity (PGIS) and
Patient Global Impression of Change (PGIC)
•Clinician Global Impression of Severity (CGIS) and
Clinician Global Impression of Change (CGIC)
Safety Endpoints  •Adverse events (AEs);
•Hematology;
•Clinical chemistry;
•Vital signs;
•Columbia Suicide Severity Rating Scale  (C-SSRS)
AEs will be recorded from the time of consent to the end of the study or patient withdrawal.  
Physical examination and v ital signs will be recorded at 
screening, baseline (no repeat of physical examination ), 1, 2, 
4, 8, 12,  16 and 20 months after the comme ncement of 
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 17 
08 JU
N 2020 Title:  Phase 2/3 Study of Arimoclomol in IBM  
continuous dosing , and at any unscheduled visits . A short -form 
physical examination is also included at months 3, 5 and 6.  
Laboratory parameters will be recorded at screening (Visit 1), 
1, 2, 3, 4, 5, 6, 8, 12, 16 and 20 months after the 
commencement of continuous dosing, and at any unscheduled 
visits . 
The C -SSRS will be assessed at all post -baseline in-clinic visits  
including unscheduled visits . 
Unscheduled visits that are solely for the purpose of refilling 
medication do not require any of the saf ety assessments. 
Othe r Endpoints   Exploratory endpoints include:  
•Population pharmacokinetics (POP PK) and exposure
response analysis.
•Presence of
•  (s
ub-study in sel
ected 
sites only; in a subset of patients ) 
Study Drug and 
dosage form  Arimoclomol 200 mg capsules and matching placebo.  
Doses to be studied, Dosing route and regimen  Two c apsules of investigational medicinal product  (IMP), each 
containing 200 mg (400 mg total arimoclomol or placebo) will 
be administered orally t.i.d.  
If required, the IMP can be dispersed in 10-30 mL (i.e. 1- 2 
tablespoons ) of liquid or in a tablespoon of soft foodstuff.  
Dispersed in water , the IMP can also be administered via a 
gastric tube (as applicable). 
IMP interuption, 
rechallenge and 
permanent discontinuation If a patient experiences an intolerable adverse event, dosing 
may be interrupted and supportive therapy administered as 
required. All dosing interruptions must be discussed with the 
contract research organization (CRO)’s medical monitor.  
An interruption of up to 4 weeks (calculated from the first day of interruption) is permitted following discussion with the CRO’s medical monitor prior to resuming IMP. The interruption of the dose should be as short as possible.  
Re-challenge with IMP in cases of increased transaminases 
should only be done in accordance with section  6.5.2
 of the 
protocol.  
If the patient experiences the same intolerable adverse event after re -
challenge with the full dose of IMP, the dose can be 
reduced to half, i.e., 200 mg t.i.d., following discussion with the 
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 18 
08 JU
N 2020 Title:  Phase 2/3 Study of Arimoclomol in IBM  
CRO’s medical monitor. The patient must continue this dose 
for the remaining part of the study. If this dose is not tolerated, 
the IMP must be discontinued permanently. This sequence of events can be implemented only once for intolerable AEs within 
a given organ/body system. If the patient experiences a 
different intol erable AE within a different organ/body system, 
this sequence of events can be repeated for that AE.  
Randomization Randomization will be stratified by center and will include 
blocking to facilitate approximate balance in the number of 
subjects assigned to each treatment group within each center.   
Selection Criteria  Inclusion criteria  
Study subjects must meet all of the following criteria which 
must be documented in the study site source documents : 
1.Meet any of the European Neuromuscular CentreInclusion Body Myositis research diagnostic criteria 2011categories  for IBM.
1 (see Appendix 1)
2.Demonstrate being able to arise from a chair without
support from another person or device
3.Able to ambulate at least 20 ft/6 meters with or without
assistive device. Once arisen from the chair, participantmay use any walking device, i.e. walker/frame, cane,crutches, or braces. They cannot be supported by another
person and cannot use furniture or wall for support.
4.Age at onset of weakness > 45 years
5.Body weight of > 40 kgs
6.Able to give informed consent
Excl
usion Criteria  
Study subjects must not meet any of the following criteria which 
must be documented in the study site source documents:  
1.History of any of the following excludes subjectparticipation in the study: chronic infection particularly HIVor Hepatitis B or C; cancer other than basal cell cancerless than five years prior, or other chronic serious medicalillnesses.
2.Presence of any of the following on routine bloodscreening: WBC  < 3000; platelets <  100,000;
hematocrit  < 30%; BUN > 30 mg/dL ; creatinine > 1.5 x
upper limit of normal; symptomatic liver disease withserum albumin < 3 g/dl
3.History of most recent creatine kinase >15x the upper limit
of normal without any other explanat ion besides IBM.
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 19 
08 JU
N 2020 Title:  Phase 2/3 Study of Arimoclomol in IBM  
4.History of non -compliance with other therapies.
5.Use of testosterone except for physiologic replacement
doses in case of androgen deficiency. Participants musthave documented proof of the androgen deficiency.
6.Coexistence of any other disease that would likely to affectoutcome measures.
7.Drug or alcohol abuse within past three months. Patienthas recent history (within 6 months before Screening) of
chronic alcohol or drug abuse which may compromise thepatient’s safety or ability to participate in study activities.Cannabis for IBM symptoms will be allowed (where legal) .
8.Par
ticipation in a recent drug study in the last 30 days
prior to the screening  visit or use of biologic agents less
than 6 months  prior to the screening visit .
9.Women who are lactating or pregnant, or  sexually active
female subjects of child- bearing potential* intending to
become pregnant or unwilling to use a highly effectivemethod of contraception** during the trial through 1 monthafter the last dose of trial medication. S exually active
male s with female partners of child- bearing potential*
unwilling to use a condom with or without spermicide in
additi on to the birth control used by their partners during
the trial until 3 months after the last dose of trialmedication unless surgically sterile (vasectomy).
*Non
 child -bearing potential is defined as post -menopausal
(minimum of 12  months with no menses  and follicle-
stimulating hormone in the post -menopausal range) or 
sterilisation (hysterectomy, oophorectomy, or bilateral tubal ligation).  
** Highly effective methods of contraception include combined 
(oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, or transdermal); progestogen- only hormonal 
contraception associated with inhibition of ovulation (oral, injectable, or implantable); intrauterine device; intrauterine hormone- releasing system; bilateral tubal occlusion; and 
vasectomised partner.  
According to the recommendations from the Clinical Trial 
Facilitation Group (CTFG, 2014), sexual abstinence is 
considered a highly effective birth control method only if it is defined as refraining from heterosexual intercourse 
during the trial until 1 month after the last dose of trial 
medication  (for female subjects of child -bearing potential) 
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 20 
08 JU
N 2020 Title:  Phase 2/3 Study of Arimoclomol in IBM  
and for 3 months after the last dose of trial medication  (for 
male subjects with female partners of child -bearing 
potential). The reliability of sexual abstinence needs to be 
evaluated by the investigator in relation to the duration of the clinical trial and the preferred and usual lifestyle of the subject.
 
10.Par
ticipants taking >7.5 mg prednisolone or equivalent or
participants on intravenous immunoglobulin ( IVIg) or other
immunosuppressants within the last  3 months.  Topical, nasal,
and ocular corticosteroids are allowed unless they are beingwidely applied or the severity of the underlying conditionmakes them unsuitable in the Investigator’s opinion. Localsteroid injections are allowed.
11. Cl
inically significant renal or hepatic disease, as indicated
by clinical laboratory assessment ( results ≥3 times the
upper limit of normal [ULN] for alanine aminotransferasecombined with bilirubin ≥2 times the ULN ; symptomatic
liver disease with serum albumin < 3 g/dL; 
or creatinine
≥1.5 times the ULN). Laboratory tests may be repeatedonce at screening. Reasons to repeat laboratory tests mayinclude that the medication causing laboratory abnormalitywas suspended, any other suspected cause may no
longer exist, or to rule out laboratory error.
Total Sample Size  Up to 150 patients will be randomized in the study, final target 
is 150 patients with the aim of achieving 75 evaluable patients in each of the two groups (Arimoclomol and Placebo).   
Number of Planned Visits  Following the screening and baseline visits, Visits 3 to 7 are to 
occur every 30 days (± 7 days) and the remaining visits are t o 
occur every 60 days relative to baseline (± 7 days). In -person 
follow- up visits at the trial site are to occur at Months 1, 2, 3, 4, 
5, 6, 8, 12, 16, and 20. Phone calls will be made at Months  10, 
14, 18, and 21. If a patient must stop the trial medication for 
any reason, every effort will be made to have the patient 
participate in each subsequent visit as scheduled.  
Statistical Methods  Analysis of the Primary Endpoint  
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 21 
08 JU
N 2020 Title:  Phase 2/3 Study of Arimoclomol in IBM  
The primary analys is of the primary estimand  will be based on 
the FAS using all observations from schedueld in-clinic  visits 
regardless of treatment adherence and used of concomittant 
medication. The analysis is a Mixed Model for Repeated 
Measurements (MMRM). The independent effects included in 
the model are treatment interacting with visit, trial centre as a separate ma
in effect and baseline IBMFRS interacting with 
visit. An unstructured covariance matrix for IBMFRS 
measurements within the same patient will be used, hereby 
assuming that measurements from different subjects are 
conditionally independent.  Only the in- clinic assessments of 
IBMFRS will contribute d ata to the primary analysis, whereas 
the assessments of IBMFRS conducted by telephone will be 
included in explorative analysis only.  
To investigate the sensitivity of the primary analysis results, 
complementary and separate analyses will be performed for 
the primary estimand. The change from baseline in IBMFRS 
total score will also be assessed for the secondary estimand 
using an MMRM analysis. The MMRM will be based on all 
observed IBMFRS -data from scheduled visits during the on-
treatmemt period.   
Further details on analyses of the secondary estimand and 
sensitivity analyses will be provided in the SAP . 
Anal
ysis of Secondary Endpoints 
The Secondary endpoints will be analysed for both the primary and secondary estimands using the same 
imputation and 
analysis set -ups as described for IBMFRS.   
All statistical tests will be conducted at the 0.05 significance 
level using 2- tailed tests, and P values will be report ed. 
Corresponding 95% confidence intervals (CIs) will be 
presented for statistical tests . 
Adverse events (AEs)  will be summarized by treatment group, 
maximum severity, and perceived relationship to study 
medication.  
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 22 
08 JU
N 2020 Title:  Phase 2/3 Study of Arimoclomol in IBM  
Continuous measures of safety (vital si gns, laboratory test 
results) will be presented using descriptive statistics and the 
C-SSRS will be summarized .
Compliance data will be summarized by treatme nt group, 
overall and by visit.  
CONFIDENTIAL
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 24 
08 JU
N 2020 3 INTRODUCTION: BACKGROUND INFORMATION AND SCIENTIFIC 
RATIONALE 
3.1 Background Information 
3.1.1 Name and D escription of the Investigational Product  
The University of Kansas Medical Center  (KUMC) and University College of London (UCL) 
Institute of Neurology in collaboration with Orphazyme A /S are developing arimoclomol 
for sporadic inclusion body myositis ( sIBM).  
Arimoclomol was originally developed for the treatment of Amyotrophic Lateral Sclerosis (ALS) by the small biotechnology company Biorex R&D renamed  CytRx Corp.  and the 
drug is now owned by Orphazyme. The investigational product, arimoclomol, was 
supplied to KUMC to conduct investigator initiated clinical trials in IBM. A Phase 2 clinical 
study in 24 IBM patients was conducted under the investigator IND  076773 ( IND Sponsor : 
Dr. , KUMC).   
Arimoclomol (/+/- (2R),(Z)-N- [2-hydroxy -3-(piperidin -1-yl)propoxy] -pyridine -1-oxide-3-
carboximidoyl chloride citrate (1:1)) (BRX -345) is an analog of bimoclomol, a 
hydroxylamine derivative that acts as a co- inducer of “heat shock” or “molecular 
chaperone” gene expression.  Although the precise molecular mechanism of action of 
arimoclomol is not known, the compound has been shown to co- induce molecular 
chaperone genes, meaning that it further elevates the chaperone protein levels already  
induced by physical or metabolic stresses in cell lines and in isolated cells/tissues (see Figure 1). It apparently accomplishes this by stabilizing the active phosphorylated trimer of the transcription factor,  Heat Shock Factor -1 (HSF -1). Recent evidence suggests 
protein misfolding and aggregation play a key role in pathogenesis in IBM. Indeed heat 
shock protein- 70 (HSP70 ) levels have been shown to be increased in IBM muscle 
biopsies. Arimoclomol may slow down the process of protein misfolding and aggregation 
in IBM by helping the muscle fiber to up- regulate inducible heat shock proteins. It may 
also slow progression of muscle degeneration in this progressively debilitating disease.   
CONFIDENTIAL
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 26 
08 JU
N 2020 subunit p65 nuclear staining was reduced from 43% in untreated cultures to 23% in 
arimoclomol -treated cultures (p<0.05). Finally, examination of ER calcium handling and 
markers of ER stress revealed that β- APP transfection resulted in a significant reduction 
in ER [Ca2+] (an indicator of ER stress), compared to empty vector treated controls 
(190nM compared to 280nM; p<0.05), a deficit that was completely prevented by arimoclomol (ER [Ca
2+] 290nM). This dramatic and beneficial effect of arimoclomol on ER 
stress was reflected in a reduction in the expression of the ER stress markers C-enhancer -binding protein homologous protein ( CHOP) and binding immunoglobulin
protein (BiP) in arimoclomol -treated β-APP transfected myotubes, compared to untreated
cultures.
3-5
Together
 these results indicate that arimoclomol ameliorates several key pathological 
features of IBM -like pathology, at least in an in vitro model of the disease (see Figure 2). 
Figur
e 2. Over -expression of 
β-APP and exposure to 
inflammatory mediators induces IBM like pathology in cultured 
myocytes which is ameliorated by treatment with arimoclomol  
Formation of cytoplasmic inclusion bodies in myocytes immunoreactive for (a) β -APP and ubiquitin and (b) 
TDP- 43. The bar chart (c) shows 
the percentage of myocytes containing ubiquitinated inclusion bodies. (d) Expression of TDP -43 
(green) following β -APP 
transfection and arimoclomol 
treatment and (e) quantification of the number of cells with cytoplasmic mislocalization of 
TDP- 43. (f) TDP -43 expression 
(green) following exposure to inflammatory mediators and arimoclomol treatment and (g)quantification of TDP -43
misloc alization in inflammatory
mediator exposed cultures.
(h)Western blot analysis of TDP -43 expression in myocyte cultures exposed to
inflammatory mediators in the presence and absence of arimoclomol. (i) Images showthe expression of NFkB subunit p65 (green)  in β-APP transfected cultures (DAPI
labelled nuclei in blue) and (j) cultures exposed to inflammatory mediators, in thepresence and absence of arimoclomol. (k) The bar chart shows the percentage of cells
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 27 
08 JU
N 2020 with nuclear NFkB subunit p65 under all culture conditions investigated. Error 
bars = S.E.M; Scale bars: a, b =10μm, d, i and j =20μm 
3.1.
2.2 In Vivo Model of IBM  
Professor  has recently completed an efficacy trial of arimoclomol in a 
mouse model which recapitulates several key features of IBM.6 Patients with an A232E 
mutation in valosin- containing protein (VCP), a protein involved in numerous cellular 
functions including protein degradation, present with a condition called inclusion body myopathy with Pagets’ disease and frontotemporal dementia (IBMPFD). Transgenic mice over-expressing the same human mutation in VCP display a muscle pathology that 
closely resembles that of IBM, including muscle weakness and histopathological signs of IBM such as rimmed vacuoles and TDP -43 and ubiquitin -positive pathology.  Dr. 
Greensmith’s team treated mutant VCP (mVCP) mice treated with arimoclomol (120 mg/kg per day, orally, in drinking water) from the start of symptom onset at 4 months 
until 14 months of age, a late stage of disease. Transgenic mice over -expressing 
wild-type human VCP (wt -VCP) were used as controls, and 10 male mice per group were 
studied. Muscle strength was assessed longitudinally by performing grip- strength 
measurements fortnightly from the start of treatment (see Figure 3a). In addition, muscle force was also established using isometric muscle force measurements performed on 
terminally anaesthetized mice at 14 months of age ( Figure 3b,c). In control wt- VCP mice, 
there was no significant reduction in grip strength relative to body weight between 4 
(6.44g +/- 0.49 SEM) and 14 months of age (5.91g +/- 0.62 SEM). In contrast, in mVCP 
mice, there was a 44.1% reduction in grip strength during the same period (from 7.19 g 
+/- 0.39g SEM to 4.02g +/ - 0.3g SEM). However, in mVCP mice treated with arimoclomol, 
there was no significant reduction in grip strength over time; with only a mild reduction from 6 .24g +/ - 0.42g SEM to 5.18g +/- 0.34g SEM by 14 months. These longitudinal 
readouts of muscle strength were reflected in the maximal tetanic force measurements obtained from extensor digitorum longus (EDL) muscles of mice examined at 14 months of age. In mVCP mice, EDL muscles generated significantly less force (16.59g +/ - 1.86 g 
SEM) than EDL muscles in wt -VCP controls (24.18g +/ - 1.94g SEM). However, in  
arimoclomol treated mVCP mice, there was no significant difference in the force output of EDL muscles (22.47g+/ - 1.84g SEM) compared to controls. These results show that 
treatment with arimoclomol prevents the loss in muscle force that occurs as disease progresses in mVCP mice.  
Hi
stological assessment of the hindlimb muscles of mVCP mice showed remarkable 
pathological changes which correspond with characteristic IBM features seen in patient muscle biopsies ( Figure 3d,e). Tibialis anterior (TA) muscles of mVCP mice showed clear 
signs of degenerating and atrophied fibers of irregular sizes, infiltration of inflammatory cells, presence of vacuoles and proteinaceous aggregates. Furthermore, an increase in the number of centralized nuclei was observed which is regarded as a feature of regenerat ing muscle fibers. Examination of muscle from arimoclomol treated mVCP mice 
however showed a greatly reduced level of degenerating and atrophied fibers ( Figure 3f). 
Quantification of the number fibers containing centralized nuclei showed that Arimoclomol treated mVCP mice had significantly more fibers with centralized nuclei 
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 28 
08 JU
N 2020 (35.28%  +/- 4.51% SEM) compared to untreated mVCP mice (18.67%  +/- 3.43% SEM) 
or wt -VCP mice (3.09% +/ - 3.39% SEM), suggesting a greater extent of regeneration in 
the muscle of arimoclomol treated mice.  
Si
nce arimoclomol is known to be a co- inducer of the HSR,  also 
examined whether the beneficial effects of arimoclomol on the muscle pathology in 
mVCP mice was reflected in a change in expression of H SP70.  As can be seen in  
Figure 3h, Western blot analysis of muscle from mVCP mice treated with arimoclomol  
showed a two- fold increase in the expression of HSP70 compared to that of untreated 
mVCP mice.  
The res
ults of this in vivo  efficacy study in a mouse that models key aspects of IBM 
confirm that treatment with arimoclomol prevents the decline in muscle strength and improves the histopathological characteristics of IBM, most likely as a result of an upregulation in H SPs. 
Figure 3 . Treatment with arimoclomol 
prevents the loss in muscle force and appearance of IBM -like pathology in mutant 
VCP mice  
a) Longitudinal analysis of grip strength shows that
there is a significant decline in grip strength inmVCP mice between 4 and 14 months of age
which is prevented in mice treated witharimoclomol. b) Typical traces of maximum tetanicforce of EDL muscles in anaesthetized mVCP andarimoclomol treated mVCP mice are shown. c)The bar chart shows that treatment with
arimoclomol prevents the loss in EDL force that occurs in mVCP mice by 14 months of age. Histopathological (H&E) analysis of TA muscles reveals the presence of key IBM -like 
pathological characteristics in mVCP mice. Compared to wt -VCP mice (d) TA muscles 
from mVCP mice (ei -v) show atrophied and degenerating fibers, inflammatory cell 
infiltration, centralized nuclei and the presence of rimmed vacuoles. In contrast, TA muscles from mVCP mice treated with arimoclomol shows few if any of these pathological changes (f). Quantification of the number of fibers with centralized nuclei (g) shows that there is a significant increase in the number of fibers with centralized nuclei in arimoclomol -treated mVCP TA muscles which is indicative of active regeneration. h ) 
Western blot analysis shows that here is a significant increase in the expression of HSP 70 
in TA muscles of mVCP mice treated with arimoclomol, compared to either unt reated 
mVCP or wt -VCP mice.
6
3.1.3 Summary of Human Clinical Pilot Research Data  
A randomized controlled pilot study in 24 IBM subjects, 18 of whom received arimoclomol 100 mg PO TID for four months and 8 were on placebo.
6 The IBM functional rating scale 
(IBMFRS) decline at 1 year was less in the arimoclomol group compared to placebo with the p value approaching significance at 8 months. Res ults from the clinical 
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 29 
08 JU
N 2020 proof -of-concept trial in IBM patients showed that arimoclomol was both safe and well 
tolerated, and identified a promising positive trend of effect on disease outcome measures 
although the study was not powered for efficacy.  
3.1.4 Discussion of Important Literature and Data that are Relevant to t he Trial a nd that 
Provide Bac kground for the Trial  
IBM is the most common progressive and debilitating muscle disease beginning in persons over age 50 years, with an annual incidence estimated at 2.2 to 7.9 per million .
8-16,20 Because biopsies of IBM muscle contain lymphocytic inflammatory cells, 
IBM was originally grouped with the inflammatory idiopathic myopathies: polymyositis and 
dermatomyositis.  However, pathologic studies during the past 25 years have clearly 
defined it as a unique pathogenic entity.17,18 IBM is a progressive, debilitating disease 
causing both proximal and distal muscle weakness, characteristically most prominent in the quadr iceps and finger flexors.
19-21 Over time it can lead to severe disability, including 
falls due to quadriceps muscle weakness and foot drop, dysphagia, and eventually respiratory muscle weakness.
11,19, 22-23 Spora dic inclusion body myositis (sIBM) is the 
most frequently occurring form of IBM ; hereditary forms of IBM occur very rarely. s IBM 
seldom affects patients under 40 and is much more common over the age of 50. Men are affected more frequently than women.
24 The natural history of IBM has been followed 
prospectively in three studies.25,26 ,29 Rose et al. followed 11 subjects for six months, and 
found an overall four percent decrease of strength from baseline.26  Data collection from 
136 IBM patients from the Paris and Oxford groups  was completed either during a clinic 
visit (52%), or by extraction from previous medical records (48%). After a median duration of 14 years from onset, 75% of patients had significant walking difficulties and 37% used 
a wheel chair.
29 Patients were treated with immunosuppression agents (prednisone, 
intravenous immunoglobulins, methotrexate or azathioprine) for a median duration of 41 
months were more severely disabled on last assessment. In a 12- year follow -up study, 
46/64 Dutch patients with sporadic IBM follow -up patients had died; with six patients 
(13%) having end- of-life car e interventions.60 The high frequency in sIBM is about 
one-third of the rate found in amyotrophic lateral sclerosis, and it highlights the heavy 
disease burden in the final stage. While life expectancy is not shortened, the causes of death differed from an age- matched Dutch general population in that aspiration 
pneumonia was significantly more frequent as a cause of death in sIBM. In another study, patients with sIBM who were aged 41 years and older had an approximately 7 -fold higher 
risk of premature mortality than the age -matched external comparison population 
(standard mortality ratio [ SMR] , 6.58; 95% CI, 5.6 –7.7). As expected, the risk of 
premature mortality in patients with sIBM decreased with increasing age, but was still approximately 5 -fold higher than the age- matched external comparison population in 
patients over 70 years of age (SMR, 4.82; 95% CI, 3.9– 5.9).
61 There is also preliminary 
evidence for increased mortality in sIBM patients who harbor 
62
We per
formed a retrospective chart review of 51 IBM cases from the Uni versity of 
Kansas.18,30 After a 7.5 -year mean disease duration, 56% of our cases required an 
assistive device, with 20% requiring a wheelchair or motorized scooter ( Table 1).18
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 30 
08 JU
N 2020 Tabl
e 1: Retrospective chart review of IBM from 2000 to 2010 at KUMC  
Male:  female ratio  1.7:1  
Ethnicity (n=51)  49 Caucasian; 2 Hispanics  
Mean age at onset (yrs) 61 (45 -80) 
Symptom onset before age 50 yrs: 12% 
Mean time to diagnosis (yrs)  5.1 (1 -15) 
Mean follow up period (yrs) 2.5 (0.5 -8) 
CK (IU/L)  609 (59 -3000)  
Nerve conductions with axon loss 
neuropathy  32% 
Electromyography  60% irritative myopathy  
12% non- irritative myopathy  
28% mixed neuropathic/ myopathic 
pattern  
Asymmetry 90% 
Non-dominant side weaker  85% 
Typical phenotype:  
Weak Finger Flexor (FF) and quadriceps 
(quads)  39/51 (76%):  
13 - Classic phenotype (FF and quads 
weakest)  
11 - Classic FF, no preferential quads 
weakness  
 6  - Classic quads, no preferential FF 
weakness  
 9  - FF and quads weak but not weakest  
Atypical phenotype  12/51 (24%):  
5/12: classic FF with leg weakness sparing quads  
4/12: limb- girdle weakness  
3/12: other atypical phenotypes (FF arm only,  hip flexion/ankle dorsiflexion, 
facioscapulohumeral)  
Muscle pathology  43: inflammation and rimmed vacuoles  
8: phenotypic IBM with inflammation but 
no vacuoles  
Mobility Outcome  75%: recurrent falls  
56%: assistive device use at mean 7.5 years  
20%: wheelch air or scooter  
Bulbar dysfunction  51%: dysphagia  
55%: facial weakness  
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 31 
08 JU
N 2020 3.1.4.1 Pathology 
There is also myonuclear degeneration early on in IBM because the majority of rimmed 
vacuoles are lined with nuclear membrane proteins. IBM myonuclei are often abnormally filled with neurofilaments and this may be the earliest detectable pathologic change in IBM.
10
In I
BM, myofibers contain nonnuclear sarcoplasmic TDP -43 accumulations together with 
a reduction of the normal nuclear TDP -43 content. This suggests that TDP -43 has 
redistributed from nuclei to sarcoplasm in a large percentage of IBM myofibers.31 The 
extranuclear accumulation of TDP -43 may be toxic to cells perhaps through altered 
binding to and splicing of mRNA. There are similarly cytoplasmic aggregates of sequestosome 1/p62 (referred to from here on as p62) which is encoded for by the SQSTM1 gene. This multifunction protein participates in the autophagy pathway and transduction pathways such as nuclear factor kappaB (NFkB) signaling and apoptosis.
32 
Immunohistochemically, TDP -43 and p62 were the most sensitive markers, accumulating 
in all definite IBM and in 31% and 37%, respectively, of possible IBM cases.33 Therefore, 
IBM muscle accumulates multiple toxic protein aggregates suggesting a disorder of protein homeostasis.  
The degen
erative theory of IBM hypothesizes that IBM is a degenerative muscle disease 
occurring in an aged cellular environment, associated with cellular accumulation and aggregation of several proteins, involving abnormal signal transduction and transcription, protein misfolding, inhibition of the cellular protein degradation pathway, and 
mitochondrial dysfunction.
34 The lymphocytic infiltrate is considered likely to be secondary 
to muscle fiber degeneration.   
A m
odel of pathogenesis in IBM has been proposed (see Figure 4).35 In this model the 
aging muscle intracellular environment, combined with environmental factors like 
oxidative stress, viruses, or other toxins, and in combination with mutations in predisposing genes leads to up- regul ation of Аβ precursor protein. This leads to abnormal 
accumulation of Аβ 40 and 42 fragments.  The Аβ 42 fragment in particular has a 
hydrophilic face and tends to aggregate into cytotoxic oligomers.  Increased transcription 
of Аβ precursor protein leads to up- regulation of other proteins which co- aggregate with 
Аβ fragments. The effects of these toxic oligomers cause oxidative stress in the cell, 
phosphorylation of tau protein, an increase in misfolded proteins, and inhibition of the protea some protein degradation pathway. This creates a positive feedback cascade. The 
cell increases its levels of heat shock proteins to help counteract this increase in misfolded proteins, in particular HSP70, but cannot keep up with increasing levels of toxic protein products. This upregulation of Аβ precursor protein can also lead to mitochondrial defects, 
further exacerbating the cycle.  In support of this theory, cultured muscle fibers with 
overexpr essing Аβ precursor proteins display similar pathology to that seen in human 
IBM muscle biopsies. Accumulation of these misfolded proteins eventually leads to the 
characteristic Аβ amyloid inclusions and paired helical fibers containing phosphorylated tau seen in IBM muscle biopsy specimens.
34,36-38
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 32 
08 JU
N 2020 Figur
e 4. Proposed pathogenic cascade of sIBM35
3.1.
4.2 Protein Misfolding  
Many systemic and neurodegenerative disorders, termed ‘protein- misfolding disorders’ 
are characterized by the accumulation of intracellular or extracellular protein 
aggregates .38 The initiating event in the disease process may be a crucial conformati onal 
change that occurs in the disease protein, possibly mediated by physical trauma, oxidative damage, or an infectious agent that leads to protein aggregates. These aggregates, or more likely their intermediate oligomeric precursor forms, can act to catalyze the process of additional aggregation, accelerating the “sequestration” of the normal protein and potentially trapping other important proteins that are prone to aggregation. In most instances these aggregated protein products are found to be cytotoxi c, although the exact mechanism of toxicity is unclear.   
A hi
ghly conserved class of proteins called molecular chaperones has evolved to prevent 
inappropriate interactions within and between non- native polypeptides, to enhance the 
efficiency of de novo p rotein folding, and to promote the refolding repair of proteins that 
have become misfolded as a result of cellular stress39-42 (see Figure 5). In addition to this 
protein repair activity, chaperones can mediate targeting to the proteasome system or to lysosomes, resulting in selective degradation of the misfolded protein when the chaperones cannot repair the misfolded proteins. These activities of the molecular chaperones may be sufficient to prevent the normal accumulation of misfolded proteins. Under conditions of cellular stress, chaperone activity is increased, adjusting to the consequent increase in damaged proteins. However, under certain pathological conditions (perhaps due to prolonged exposure during chronic disease), the capacity of this protein quality control machinery can be exceeded, and misfolded proteins accumulate to dangerous levels.  
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 33 
08 JU
N 2020 Figur
e 5. Schematic of the m echanism of action of HSP7040 
3.1.
4.3 Primary Endpoint: IBMFRS  
The Inclusion Body Myositis Functional Rating Scale (IBMFRS) is a quickly 
administered (10- minute) ordinal rating scale (ratings 0- 40) used to determine patients' 
assessment of their capability and independence in 10 funct ional activities. The scale 
was developed by the Muscle Study Group ( MSG ) investigators and was utilized in the 
beta-interferon- IBM trials .27,28 All 10 activities are relevant in IBM . The advantages of 
the IBMFRS are that the categories are relevant to IBM, it is a sensitive and reliable tool for assessing activities of daily living function in patients with IBM, and it is quickly administered.  In the beta- interferon trial, the IBMFRS correlated well with MVICT, 
MMT, SF -36, and the Amyotrophic Lateral Sclerosis Functional Rating Scale 
(ALSFRS) .
43  
The IB
MFRS ( see Appendix 2) was derived from the ALSFRS which is another 
patient -derived subjective scale currently accepted as the primary endpoint measure 
for nearly all ALS clinical trials for the last 15 years. The IBMFRS has been validated 
in its use with IBM patients as it correlated well with objective strength measures (Maximum Voluntary Isometric Contraction and Manual Muscle Testing) and quality of life as assessed by the SF- 36.
44 Recently, we presented an analysis of prospective 
IBMFRS data collected over several years in 127 IBM cases from the UK and USA .44  
The IB
MFRS  includes 10 measures (swallowing, handwriting, cutting food and 
handling utensils, fine motor tasks, dressing, hygiene, turning in bed and adjusting covers, changing position from sitting to standing, walking, and climbing stairs), each graded on a Likert scale from 0 (being unable to perform) to 4 (normal). Sum of the 10 items gives a value between 0 and 40, with a higher score representing less functional limitation.   
3.1.5 Importance of the Study and Any Relevant Treatment Issues or Controversies  
In the US, the true prevalence of IBM is unknown, but is conservatively estimated at 5- 10 
cases  per million and the upper end of the prevalence estimate range is 71 per million.
8 
There are no effective treatments for IBM; the patient’s disease continues to progress 
CONFIDENTIAL
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 35 
08 JU
N 2020 exposed to inflammatory mediators, suggesting lower levels of cell stress. Indeed, both 
β-APP over -expression and inflammatory mediators induced cell death, which was 
significantly reduced by arimoclomol.  
Nuclear translocation of the NFkB subunit p65 was examined as an indication of NFkB activation, which was observed following exposure to IL1β and TNFα. β -APP 
over-expression also induced NFκB activation, in keeping with cellular models of 
Alzheimer’s disease, in which Aβ42 has been shown to activate the inflammatory  
cascade.
46 Arimoclomol had an inhibitory effect on NFκB activation in both models, which 
is like ly to reflect HSR augmentation, given the established ability of HSPs to 
down- regulate t he NFκB cascade.47
Arimoclomol also significantly reduced the disruption in ER calcium homeostasis induced in both IBM models and consequently reduced the ER stress response, a key mechanism involved in handling aberrant proteins.
6 This was reflected by restoration of cytosolic 
calcium levels towards control levels. Indeed, in TNFα treated cultures, the reduction in cytosolic calcium was entirely prevented by arimoclomol, as was the expression of the ER stress mediator CHOP. This protective effect of arimoclomol is likely to reflect, at least in part, the chaperone activity of augmented HSP70 levels which serves to improve the efficiency of protein handling and repair or degradation of misfolded proteins.  
Examination of the two major protein degradation pathways in the culture models revealed disruption in both proteasome function and increased autophagy. However, 
arimoclomol had no effect on proteasome function, although formation of mature autophagosomes was reduced, suggesting a reduced misfolded protein load in the lysosomal pathway.  
In vivo,  treatm ent of mVCP mice with arimoclomol between 4- 14 months of age 
significantly improved the pathological features and functional deficits characteristic of the inclusion body myopathy.
6 Thus, in arimoclomol -treated mVCP mice an increase in 
muscle strength was observed and a reduction in key pathological hallmarks of IBM, including a decrease in ubiquitin expression and a reduction in cytoplasmic 
mis-localisation of TDP -43, accompanied by an increase in HSP expression.  
Previous experimental clinical trials in IBM have only tested agents directed at the inflammatory component of pat hology and all were ineffective.
10,13,48- 50 Whether the 
degenerative aspect of IBM is primary to the pathogenesis or not, it very likely plays a role in the deleterious effects in muscle, and may be a potential therapeutic target. Protein homeostasis (proteostasis) is essential for normal cellular functions
3 and in conditions of 
cellular stress, proteins can become unfolded or misfolded, leading to their aberrant aggregation.
4 
Protein misfolding is normally managed by  endogenous chaperone proteins5, which 
prevent aberrant protein- protein interactions and promote correct protein folding. HSPs 
are a family of ubiquitously expressed protein chaperones, which are up- regulated 
following stress -induced activation of the heat shock response (HSR), an endogenous 
cytoprotective mechanism. Since the HSR declines with advanced age2, up-regulation of 
the HSR in disorders in which there is evidence of protein mishandling, such as IBM, may be of therapeutic value.  
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 36 
08 JU
N 2020 A randomized controlled pilot study was conducted in 24 IBM subjects, 18 of whom 
received arimoclomol 100 mg PO TID for four months and 8 were on placebo. The IBM functional rating scale (IBMFRS) decline at 1 year was less in the arimoclomol group compared to placebo with the p value approaching significance at 8 months. Res ults from 
the clinical proof -of-concept trial in IBM patients showed that arimoclomol was both safe 
and well tolerated, and identified a promising positive trend of effect on disease out come 
measures although the study was not powered for efficacy.  
These findings provide compelling evidence of the beneficial effects of arimoclomol in in 
vitro and in vivo  models of IBM, which support clinical assessment of its effects in IBM 
patients. However, up- regulation in HSP expression by arimoclomol was clearly 
established in both the in vitro  and in vivo  models, as previously reported.
42 
A Type C guidance (written responses only) was received under IND 076773 from the Food and Drug Administration ( FDA) with regards to a Phase 2/3 protocol with on 
21 June 2016 (Reference ID 3948721). Initially, the Sponsor proposed 0 mg (placebo), 
100 mg t.i.d and 200 mg t.i.d. as the doses for the protocol. FDA recommended to select 
a higher dose that may be closer to the maximum tolerated dose. Therefore, clarification was sought on behalf of the Sponsor of the IND regarding the proposed doses for the 
protocol, where the doses of 0 mg (placebo), 200 mg t.i.d and 400 mg t.i.d. were proposed. The Agency agreed to the higher dosing of 400 mg t.i.d. and the proposal to increas e the lower dose to 200 mg t.i.d. Statistical evaluation has shown that to perform 
a three arm study, we would need to double our sample size to demonstrate the same efficacy as with a two arm study. Given this is a rare disease with limited total patients , 
the current study  design is a two- arm study comparing placebo versus arimoclomol 
400 mg t.i.d. 
This proposal for higher dosing (400 mg t.i.d.) is based on nonclinical safety data and previous human exposure; the nonclinical and clinical study reports are  submitted to 
IND 071269; study numbers included in parenthesis are summarized below:  
Nonclinical:  
In vitro  data 
•Dose proportionality is established in relevant in human cell line over a wide range,
10-400 μM.
•No effect on human ether -a-go-go-related gene ( hERG ) potassium channels
(ARIM -SF-001)
•No CYP Inhibition (ARIM -AD-003)
•Weak inhibitor of the OCT 2 transporter; IC50 at 10 μM (CYP0882_R1)
Toxicity data 
•19 nonclinical toxicological studies have been performed with arimoclomol in mice,rats and dogs
•Dogs: no- observed- adverse- effect- level ( NOAEL ) at 160 mg/kg/day (80 mg/kg
BID) PO determined in 52 weeks study (ARIM -TX-004)
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 37 
08 JU
N 2020 •Rats: NOAEL at 375 mg/kg/day PO determined in 28 day toxicology study in rats
•Lethal dose 1800 mg/kg PO QD. T he test item arimoclomol administered orally to
rats in doses 200, 400 and 900 mg/kg respectively over 180 days did not cause
any toxic lesions detectable by histological examination (PREST- 013)
Clinical: 
Extensive human exposure to arimoclomol  
•7 (seven) Phase I studies were completed with dose levels ranging from 50  mg to
1800 mg
•Maximum single dose administered in human being was 800 mg
•Maximum repeated dose was 600 mg t.i.d. for 5 days (AALS -005)
•Renal safety was assessed in a 28 day Phase I study with 400mg t.i.d (1200 mg
daily) or placebo t.i.d. administered for 28 days was safe and well tolerated. There
were no deaths, no serious adverse events ( AEs) and no other significant AEs.
(AALS- 010)
•Cmax observed at 1628 ng/ml (3.2 µM) (Healthy male volunteers) (AALS -010)
•Higher metabolite exposure in animals than humans
Based on the minimum safety factor of 10 for calculating the human equivalent doses, the current study highest dose of 1200 mg daily (~ 17 mg/kg based on average human 
body weight of 70 kg) is much lower than the calculated highest safe dose of 6300 mg daily, i.e. 70 kg x 90 mg (1/10 of safe dose tested in Pre- ST-013). The proposed dose of 
400 mg t.i.d. was also well tolerated in the 28- day Phase I study in healthy human 
volunteers.  The maximum tolerated dose for humans is not known but the highest dose 
used in healthy volunteers is 1800 mg/day.  
Preliminary data from the pilot Phase II clinical study indicate that arimoclomol 100 mg p.o. t.i.d. is safe and well -tolerated in IBM.
6 Given the observed positive IBMFRS and
MMT trends from the pilot study, further investigation of arimoclomol in a larger IBMpatient population is warranted. While a dosage of 100 mg t.i.d. was used in the pilotPhase 2 study, a 400 mg t.i.d. dosage will be used in the Phase 2/3 clinical study.
3.1.6 Potential Risks and Benefits 
3.1.6.1 Safety and Tolerability  
A total of 10 clinical studies with arimoclomol have been conducted: 7 studies in healthy subjects, 2 studies in patients with ALS, and 1 study in sIBM.  
Data from the completed studies indicate that arimoclomol may lead to a drug- related 
increase in serum  creatinine and a decrease in mean creatinine clearance. There was no 
change in glomerular filtration rate (GFR) and serum cystatin C, suggesting an inhibitory effect of arimoclomol on tubular secretion of creatinine. The increase in serum creatinine may be explained by a weak interaction of arimoclomol with the OCT2 transporter. See the current version of the Investigator’s Brochure for further information.  
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 38 
08 JU
N 2020 In a completed investigator initiated study in sIBM (10656), there were no significant 
differences between treatment groups regarding the rate, type, and severity of AEs. There were 8 possibly treatment -related AEs in the placebo group and 14 with arimoclomol, the 
most common being gastrointestinal.
6 
Increases in transaminases (ALT/AST) have been observed in a minority of patients treated with blinded IMP in ongoing trials with arimoclomol. The maximum increase has been above 20x upper limit of normal (ULN). The values have returned to baseline either during treatment or after discontinuation of blinded IMP.  
3.1.6.2 Known Potential Benefits  
Trials assessing immunotherapeutic agents have not demonstrated significant efficacy against IBM. In experimental cellular and animal models, arimoclomol ameliorates key degenerative and inflammatory features of IBM pathology. In a randomiz ed, 
placebo- controlled safety and tolerability trial, arimoclomol (300 mg/day) was found to be 
safe and well tolerated in sIBM patients. There was  a trend in favor of arimoclomol in 
secondary endpoints of muscle function and functional IBM scales.
6 If arimoclomol were 
found to be beneficial for the treatment of IBM, this would represent the only effective treatment for this otherwise progressive disease.  
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 39 
08 JU
N 2020 4 TRIAL OBJECTIVES AND PURPOSE 
4.1 Objectives 
4.1.1 P rimary Objective  
•To evaluate the efficacy of a rimoclomol at a daily dos age of 1200 mg (400 mg t.i.d)
compared to placebo in the treatment of sporadic IBM at 20 months.
4.1.2 Safety  Object ive 
•To evaluate the safety and tolerability of arimoclomol at a daily dos age of 1200 mg
(400 mg t.i.d.) compared to placebo in the treatment of s poradic IBM over 20
months.
4.2
 Estimands 
4.2.1 Primary Estimand  
The primary estimand – “Treatment policy” is defined as follows:  
Treatment difference of change from baseline in the IBMFRS instrument’s total score 
between arimoclomol and control at 20 months for all randomised patients regardless of exposure, adherence to randomised treatment and changes in standard of care  
The treatment policy estimand assesses the expected benefit on the IBMFRS 
instrument in a future population that results from patients being offered treatment with 
arimoclomol as add- on to standard-of- care as compared to standard- of-care alone after 
20 months of follow -up. 
Generalisation of this estimand depends among other things on the extent to which the 
standard- of-care provided in this trial reflects clinical practice and whether the 
adherence to trial product administration in this trial reflects the behaviour of the target 
population. Accordingly, data collected regardless of discontinuation of trial product or 
background therapy will be used to draw inference.  
In line with the primary estimand, the term “missing data” will be used to cover data that 
are planned to be collected but are not present in the database.  This implies that data 
that are missing due to death are considered missing and thus could meaningfully have 
been collected. The premise for using this counterfactual while- alive approach is that 
deaths are assumed relatively rare and unrelated to the disease. Details on how 
missing data are handled further and imputed are detailed in Section 
4.2.
2 Secondary Estimand  
The secondary  and supportive estimand – “Hypothetical” estimand, is defined as 
follows:  
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 40 
08 JU
N 2020 Treatment difference of change from baseline in the IBMFRS instrument’s total score 
between arimoclomol and control at 20 months for all randomised and exposed 
patients if all patients adhered to treatment . 
The hypothetical estimand assesses the benefit on the IBMFRS instrument that a future 
population would be expected to experience if the patients did not discontinue 
arimoclomol when compared to standard- of-care.  It is considered a clinically relevant 
estimand as it provides information to treating clinicians about the expected efficacy of arimoclomol compared to standard- of-care for purposes of treating individual patients. 
Generalisation of this estimand depends  among other things on the extent to which the 
adherence to trial product administration in this trial could reflect the behaviour of the target population. Accordingly, only data collected while patients were exposed to trial IMP will be used to draw inference.
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 41 
08 JU
N 2020 5 OVERALL STUDY DESIGN 
5.1 Description of the Study Design 
The clinical study will be a Phase 2/3 randomized, double- blind, placebo -controlled 
international study in 150 patients with sporadic IBM followed for 20 months. Total 
duration of the study per patient is approximately 22 months including screening and the 
end of study phone call. In this study there will be two treatment groups of 75 patients 
each, i.e., 75 patients receiving arimoclomol 400 mg t.i.d and the remaining 75 patients 
receiving placebo. There will be approximately 11 sites in the United States and 1 site in 
the United Kingdom.   
Arimoclomol will be administered at 400 mg orally three times a day in this study. 
Capsules are 200 mg so each patient will take 2 capsules three times a day. Every effort should be made to allow approximately 6 to 7 hours between dosing. As arimoclomol 100 
mg PO TID was a well- tolerated dosage in our pilot study and 200 mg PO TID was 
well-tolerated for 1 year in a familial ALS study, and safety data support the use of 400 mg 
PO TID, and since the latter dosage is felt to be appropriate based on extrapolation from our animal VCP IBM model data, we will initiate participants on the 400 mg PO TID dosage or matching placebo. The main adverse events recorded in previous studies were mild to moderate gastrointestinal events.  
If a patient experiences an intolerable adverse event, dosing may be interrupted and supportive therapy administered as required. Detailed description of the dose reduction is located in Sect ion 7.7. The patient will be followed up as planned per protocol for 
adverse events recording. Every effort will be made to continue to follow up and evaluate 
all subject s enrolled in this study.   
Upon completion of this study, qualified patients may enter an open- label extension study 
at their last treatment visit (Month 20).  
5.2  Study Endpoints 
5.2.1 Primary Endpoint  
The primary endpoint is the change from baseline to Month 20 in the Inclusion Body 
Myositis Functional Rating Scale (IBMFRS) total score.   
5.2.2 Secondary Endpoints  
Secondary endpoints of this study will involve objective endpoints that could translate into the functional strength abilities of these patients. The quadriceps muscles are targeted in this Phase 2/3 trial because of their preferential weakness in IBM and their contributio n 
to gait impairment and falls.
52 There is a correlation between quadriceps muscle strength 
and function including the distance walked at the 2- and 6- minute walk tests and timed 
tests of stair climbing, standing from a chair, and stepping up on curbs. Subjects with the 
best-preserved quadriceps strength exhibited the highest IBMFRS scores.  
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 42 
08 JU
N 2020 Secondary efficacy endpoints will include changes from baseline to Months 12 and 20 in 
the following measures of strength and function:  
•IBMFRS total score (Month 12)6 minute walk test with 2 minute distance captured
•Modified Timed Up and Go (mTUG)
•Muscle Strength Testing
oManual Muscle Testing (MMT)
oIsometric Contraction Testing of bilateral quadriceps strength using the
MicroFET
•Health Ass essment Questionnaire (HAQ - DI)
•Grip strength using the Jamar device
•SF-36
•Falls  and near falls
•Patient Global Impression of Severity (PGIS)  and Patient Global Impression of
Change (PGI C)
•Clinician Global Impression of Severity (CGIS) and Clinician Global Impression of
Change (CGIC)
5.2.2.1 Six Minute Walk Test  
The distance an IBM patient can walk in 6 minutes will be assessed. Subjects will be 
instructed to walk down one side of the track and back along the opposite side as quickly and safely as possible for 6 minutes. Subjects will be allowed to take break s as needed 
during the walking period, but timing will continue during breaks.  The distance walked in 
meters will be recorded after 2 minutes and 6 minutes.  Use of assistive device and the 
type of device during this test will be documented each time.  Instructions for 
administration of the test are provided in the Clinical Evaluator’s Manual . 
5.2.2.2 Modified Time Up and Go  
Patient’s ability to get up from a chair allowing subjects to use their arms (since most with sIBM cannot perform the task without pushing off), walk 3 meters, turn around and walk back to the chair and sit down. The use of nearby walls, or assistance from  a caregiver, 
will not be allowed. This test will be performed twice and the fastest time will be used in the data analysis. Instructions for administration of the test are provided in the Clinical Evaluator’s Manual . This objective endpoint represents a skill that is one of the first things 
that patients lose. This also can be the most debilitating loss that they will endure. Losing this function greatly hinders their ability to transfer.  
5.2.2.3 Muscle Strength Testing 
Muscle testing will be performed by three different methods. The first method is by Manual Muscle testing. 24 number of muscles will be tested. This method is routinely performed 
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 43 
08 JU
N 2020 in a clinical setting and has been shown to be reliable ( see the Clinical Evaluator’s 
Manual ).  
The second method involves using the MicroFET hand myometer  of quadriceps muscle. 
This is a hand- held device that allows the examiner to push against a muscle while the 
patient resist. Unlike the manual muscle test which provides a range, this device will 
provide an actual number. One muscle group will be  tested bilaterally (i.e., quadriceps ). 
Each muscle is tested twice while the patient is encouraged by the clinical evaluator ( CE) 
to exert maximal effort. Record the two trials generated by the patient . Effort should be 
made to keep the variability down to 15% between the two trials  (see the Clinical 
Evaluator’s Manual ). 
The third strength method is the use of a Jamar Dynamometer that will measure grip strength.  Two trials should be performed on each side ( see the Clinical Evaluator’s 
Manual ). 
5.2.2.4 Health Assessment Questionnaire 
The health assessment questionnaire ( HAQ-DI) is a self -report functional status 
(disability) measure based on the five patient -centered dimensions (death, disability, 
discomfort, drug toxicity and dollar costs). The HAQ domain of disability is assessed by the eight categories of dressing, arising, eating, walking, hygiene, reach, grip, and common activities. Discomfort is determined by the presence of pain and its severity.  
5.2.2.5 Number of Falls  and Near Falls  
Falls are common event s in the lives of IBM patients. We will record the number of falls 
and near falls every month.   
5.2.2.6 SF-36 
The SF- 36 will be performed as described in Section 8 . 
5.2.2.7 Patient Global Impression of Severity and Change  
The PGIS and PGIC  will be performed as described in Section 8 . 
5.2.2.8 Clinician Global Impression of Severity and Change  
The CGIS and CGIC will be performed as described in Section 8 . 
5.2.
2.9 Safety Endpoints   
The safety endpoints are as follows: 
•Adverse events (AEs);
•Hematology;
•Clinical chemistry;
•Vital signs;
•Columbia Suicide Severity Rating Scale  (C-SSRS)
CONFIDENTIAL
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 45 
08 JU
N 2020 6 STUDY ENROLLMENT AND WITHDRAWAL  
6.1 Trial Conduct  
This clinical trial will be conducted in compliance to this protocol, the ethical and scientific 
principles governing clinical research as set out in the Declaration of Helsinki and the 
International Conference on Harmonization (ICH) guidelines on Good Cli nical Practice 
(GCP).  
6.2 Inclusion Criteria  
Study subjects must meet all of the following criteria which must be documented in the 
study site source documents : 
1.Meet any of the European Neuromuscular Centre Inclusion Body Myositis researchdiagnostic criteria 2011 categories  for IBM.
1 (see Appendix 1)
2.Demonstrate being able to arise from a chair without support from another person ordevice
3.Able ambulate at least 20 ft/6 meters with or without assistive device. Once arisenfrom the chair, participant may use any walking device, i.e. walker/frame, cane,
crutches, or braces. They cannot be supported by another person and cannot usefurniture or wall for support.
4.Age at onset of weakness > 45 years
5.Body weight of > 40 kg
6.Able to giv e informed consent.
6.3
 Exclusion Criteria  
Study subjects must not meet any of the following criteria which must be documented in 
the study site source documents:  
1.History of any of the following excludes subject participation in the study: chronic
infection particularly HIV or Hepatitis B or C; cancer other than basal cell cancer lessthan five years prior; or other chronic serious medical illnesses.
2.Presence of any of the following on routine blood screening: WBC<3000; p latelets
< 100,000; hematocrit < 30%; BUN > 30 mg/dL ; creatinine > 1.5 x upper limit of
normal ; symptomatic liver disease with serum albumin < 3 g/dL.
3.History of most recent creatine kinase >15x the upper limit of normal without anyother explanation besides IBM.
4.History of non- compliance with other therapies.
5. Use of testosterone except for physiologic replacement doses in case of androgen
deficiency. Participants must have documented proof of the androgen deficiency.
6.Coexistence of any other disease that would be likely to affect outcome measures.
7. Drug or alcohol abuse within past three months.  Patient has recent history (within
6 months before Screening) of chronic alcohol or drug abuse which may
compromise the patient’s safety or ability to participate in study activities. Cannabisfor IBM symptoms will be allowed (where legal).
8.Participation in a recent drug study in the last 30 days prior to the screening visit oruse of a biologic agent less than 6 months prior to the screening vi sit.
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 46 
08 JU
N 2020 9. Women who are lactating or pregnant, or  sexually active female subjects of child-
bearing potential* intending to become pregnant or unwilling to use a highly effective
method of contraception** during the trial through 1 month after the last dose of trial
medication. Sexually active males with female partners of child- bearing potential*
unwilling to use a condom with or without spermicide in addition to the birth control
used by their partners during the trial until 3 months after the last dose of trialmedication unless  surgically sterile (v asectomy).
*Non
 child -bearing potential is defined as post -menopausal (minimum of 12 months
with no menses and follicle- stimulating hormone in the post -menopausal range) or
sterilisation (hysterectomy, oophorectomy, or bilateral tubal ligation).  
** Highly effective methods of contraception include combined (oestrogen and 
progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, or transdermal); progestogen- only hormonal 
contraception associated with inhibition of ovulation (oral, injectable, or implantable); intrauterine device; intrauterine hormone- releas ing system; bilateral tubal occlusion; 
and vasectomised partner.  
According to the recommendations from the Clinical Trial Facilitation Group (CTFG, 2014), sexual abstinence is considered a highly effective birth control method only if it is defined as refraining from heterosexual intercourse during the trial until 1 month 
after the last dose of trial medication (for female subjects of child- bearing potential) 
and for 3 months after the last dose of trial medication (for male subjects with female 
partners of  child-bearing potential). The reliability of sexual abstinence needs to be 
evaluated by the investigator in relation to the duration of the clinical trial and the preferred and usual lifestyle of the subject.  
10.Par
ticipants taking >7.5mg prednisolone or equivalent or participants on intravenous
immunoglobulin ( IVIg) or other immunosuppressants within the last 3 months.
Topical, nasal, and ocular corticosteroids are allowed unless they are being widelyapplied or the severity of the underlying condition makes them unsuitable in theInvestigator’s opinion. Local steroid injections are allowed.
11. Clinically significant renal or hepatic disease, as indicated by clinical laboratory
assessment (results ≥3 times the up per limit of normal [ULN] for alanine
aminotransferase combined with bilirubin ≥2 times the ULN; symptomatic liver
disease with serum albumin < 3 g/dL; or creatinine ≥1.5 times the ULN). Laboratorytests may be repeated once at screening. Reasons to repeat  laboratory tests may
include that the medication causing laboratory abnormality was suspended, anyother suspected cause may no longer exist, or to rule out laboratory error.
6.4
 Strategies for Recruitment and Retention 
The sample size will be 75 participants per group (150 total).  
There will be approximately 11 sites within the US and 1 site within the UK. The UK 
anticipates recruiting approximately 50 patients and each site within the US believes that they can recruit up to 10 patients per site.  
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 47 
08 JU
N 2020 Each site involved in this study has a large database of IBM patients and since there are 
no other current drug treatment trials involving IBM patients, we anticipate that each site would be able to recruit their patients within 1 year of start up.  The study is currently listed 
on clinicaltrials.gov.  
If necessary, letters to neurologists within each sites region will be sent if enrollment is 
slow. The Myositis Association will be contacted to assist with recruitment.  
6.5
 Participant Withdrawal or Termination 
6.5.1 Reasons for Withdrawal or Termination  
The patient will be advised in the ICF that they have the right to withdraw from the study at any time without prejudice, and may be withdrawn at the Investigator’s, or the Sponsor ’s discretion at any time. In addition, early withdrawal may occur for any of the 
following reasons : 
•Patient requests  (withdrawal by subject)
•Investigator decides that it is in the patient’s interest  (physician decision)
•Serious AE that is probably  or definitely  related to the study medication
•Death
•Failure to meet eligibility criteria
•Lost to follow -up
•Significant protocol violation
•Breaking of the blind
•Pregnancy
•Commencing systemic treatment with prednisolone >7.5 mg or equivalent
(except if short course [up to 4 weeks] administration not related to IBM e.g. due
to an asthma attack), IVIg, or other immunosuppressants
•Commencing other experimental or prohibited treatments
•Study terminated by Sponsor
•Other
6.5.
2 Handling of Participant Withdrawals or Discontinuation of Study Treatment  
In the event that the patient permanently discontinues study treatment, the patient will be encouraged to continue attending the protocol -specified study visits for continued 
assessments. 
According to the FDA Guidance for Industry on Drug- Induced Liver Inj ury (DILI) (64), IMP 
must be permanently discontinued in the case of the following:  
•ALT or AST >8 x U LN
•ALT or AST >5 x ULN for more than 2 weeks
•ALT or AST >3 x ULN and bilirubin >2 x ULN or International Normalised Ratio
(INR) >1.5)
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 48 
08 JU
N 2020 •ALT or AST >3 x ULN with the appearance of fatigue, nausea, vomiting, right upper
quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)
Re-challenge in case of increased transaminases: 
If in the Investigator’s judgement, a temporary halt in IMP is instituted because of elevated transaminases, a re- challenge must not occur if the patient had the following:  
•ALT or AST > 5 x ULN
•ALT or AST > 3 x ULN with the appearance of fatigue, nausea, v omiting, right
upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)
•ALT or AST > 3 x ULN AND bilirubin  >2 x ULN
IM
P must also be discontinued for subjects with elevated transaminases where close 
observation (repeated laboratory tests) is not possible, see Section 6.5.2 
In the event that the patient drops out of the study or is withdrawn from the study, the end of study/discontinuation page in the patient’s case report form ( CRF) should be 
completed. On the end of study/discontinuation page, the Investigator (or designee)  
should record the date of the withdrawal, the person who initiated withdrawal and the reason for withdrawal. Withdrawn patients will not be replaced.   
If a patient is unable to return to the center, a phone call will be made to the patient in 
order to complete assessments and retrieve any outstanding data. All attempts to make contact with the patient should be documented in source notes. In the event of a loss to follow up, information about the patient will be sought from the family or family physician.  
For patients who leave the study or when the study ends, normal standards of care, according to local practice, will continue as necessary.  
6.5.2.1 Premature Termination of the Study  
The Sc
ientific Steering Committee and the Sponsor may jointly decide to terminate the 
trial at any time for any reason.  
The Sponsor will terminate the study if the Sponsor determines that its investigational drug presents an unreasonable and significant risk to patients. Time permitting, the Sponsor will notify the Steering Committee and involve the Steering Committee in its decision.  
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 49 
08 JU
N 2020 The Independent Ethics Committees (IECs)/Institutional Review Boards (IRBs)  may 
recommend to the Sponsor, and the regulatory authorities  may require from the Sponsor, 
that the study is terminated for reasons pertaining to efficacy, safety or quality of the 
investigational product (arimoclomol). A decision to prematurely terminate the study will be binding to all S ite Investigators of all study cent ers. IECs /IRBs  and regulatory 
authorities will be informed about the reason and tim ing of such termination according to 
the applicable laws and regulations.  
6.5.2.2 Premature Discontinuation of Study  Participation at Individual Centres  
The Sponsor and the Scientific Steering Committee may jointly decide to discontinue this 
study in one particular or several study centre(s) for reasonable cause, including but not limited to one of the following reasons:  
•Non-compliance with GCP and/or regulatory requirement s.
•Inability of the site to be activated in a timely fashion.
•Centre cannot recruit an adequate number of patients  in a timely fashion.
•False documentation in the CRF, either deliberately or due to carelessness.
•Inadequate co- operation with the Sponsor or its representatives.
•The Investigator requests closure of his/her study centre.
If the study participation is prematurely discontinued in one or more study center s, site 
Investigators must inform their patients and take care of appropriate follow- up and fur ther 
treatment of the patients.  Independent Ethics Committees (IECs) / Institutional Review 
Boards (IRBs) and regulatory authorities will be informed about reason and time of discontinuation according to the applicable laws and regulations.  
For patients who leave during the study or when the study ends, normal standards of 
care, according to local practice, will continue as necessary.  
6.5.2.3 Regular Termination of Study  
End of study will be 22 months after recruitment of the last patient  (1 month screening 
period, 20 months treatment, 1 month follow -up), or earlier if all patients have completed 
or withdrawn from the study prior to this time point.    
Within 90 days of the end of a clinical study, the S ponsor will notify IECs /IRBs  and 
regulatory authorities about the regular termination of the study as required according to national laws and regulations.  
If the study has to be terminated early, this period shall be reduced to 15 days and the 
reasons clearly explained.  
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 50 
08 JU
N 2020 7 S TUDY TREATMENT  
7.1 Study Agent (s) and Control Description  
In this parallel -group randomized trial, subjects who meet trial entry criteria will be 
randomly assigned in a 1:1 ratio to arimoclomol or placebo. The randomization schedule 
will be computer generated using a permuted block algorithm and will randomly allocate IMP to randomization numbers. The randomization numbers will be assigned sequentially as subjects are entered into the trial.  
When all screening procedures are completed and the site investigator believes that the 
subject is eligible , the site will contact the KUMC project manager (or delegate) who will 
confirm completeness of the eCRF data prior to randomization. If the data is confirmed 
as complete, the KUMC project manager (or delegate) will perform the randomizat ion 
before the baseline visit. A randomization confirmation email will automatically be 
generated to the study site staff and management team.  Study medication bottle numbers 
to be dispensed at the baseline visit will already have been distributed to the site in 
advance of randomization.  
7.2 IMP Manufacturing 
The drug substance will be manufactured and released by Patheon ( US) and will be 
utilized to prepare hard capsules of arimoclomol citrate containing standard compendial excipients. Arimoclomol capsules are manufactured by Patheon (FR). The IMP is 
labelled, packed and released according to the IMPD.  
7.3 Formulation, Appearance, and Packagi ng 
Arimoclomol is an odourless, crystalline powder of white or off -white colour supplied in 
hard capsules of 200 mg. For each strength, capsule fill will be a powder mix of active 
pharmaceutical ingredient (API), with the remainder made of 
 and . Arim oclomol is formulated into 
size “0”, white hard capsules f or oral admi nistration. For this Phase 2/3 clinical trial, 
capsule strengt h is 200 mg.  
The placebo capsule is visually indistinguishable from the arimoclomol capsule in size and appearance. The placebo of the same size (size 0) will be presented with an identical 
weight capsule fill in identical white hard capsules and packaged and labelled as described for arimoclomol. The excipient composition, texture, appearance, solubility, smell and flavour of the placebo are carefully matched to mask the identity of the active capsule (arimoclomol).  In the placebo formulation, the API is exchanged to B itrex
® 
(denatonium benzoate) as placebo flavour masking.  
The capsules are packed in high density polyethylene (HDPE) bottles each c ontaining 
84 capsules . 
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 51 
08 JU
N 2020 7.4 Product Storage and Stability  
Clinical batches of active and placebo capsules will be placed i n a stability  study in 
accordance to International  Conference on Harmonization (ICH)  stability program . The 
stability testing will be performed on packaged product in bottles as applicable.  
In-use stability data following pre- mixing of the capsules contents into a suitable beverage 
or soft food vehicle (e.g. water, apple juice, and yogurt) as well as feeding -tube recovery 
are documented. 
Based on the available stability data, the IMP capsules are recommended to be stored at 
USP controlled room temperature, i.e., store  at 15º to 25ºC with excursions permitted 
between 2º and 30ºC.   
7.5 Preparation 
Arimoclomol citrate is a highly soluble compound with an aqueous solubility of 14 g/100 mL. Ari moclomol is formulated in size “0”, white hard capsules f or oral 
admi nistration.  
All the excipients are listed in the FDA’s inactive ingredients database.  
Arimoclomol capsules are available as oral capsules  in strengths  of 25 mg, 50 mg, 
100 mg, and 200 mg, but only 200 mg capsules  will be used for this study. The dose in 
the Phase 2/3 clinical trial is 400  mg t.i.d.  
7.6 Dosing Route and Regimen 
The IMP (arimoclomol and placebo) may be dispensed only by the site Investigator or by 
a staff member assigned by the site Investigator, as appropriate. The IMP will be dispensed to the patient during site visits or may be shipped to the patient’s house (as appropriate).  
The contents of the hard capsules can be dispersed in 10- 30 mL (i.e. 1- 2 tablespoons) of 
water, milk or juice or sprinkled on foods like apple sauce, or yogurt etc. to promote dose compliance.  
In aque ous dispersed state, the capsule content can be administered through a gastric 
tube. The tube should be flushed with 5 mL of water.  
7.7 Starting Dosage, IMP interuption, rechallenge and permanent 
discontinuation 
Dosing  will start at 400 mg 3 times a day.  If a patient experiences an intolerable adverse 
event, dosing may be interrupted and supportive therapy administered as required. All 
dosing interruptions must be discussed with the contract research organization ( CRO )’s 
medical monitor. 
An interruption of up to 4 weeks (calculated from the first day of interruption) is permitted 
fol
lowing discussion with the CRO’s medical monitor prior to resuming IMP. The 
interruption of the dose should be as short as possible.  
If the patient experiences the same intolerable adverse event after re- challenge with the 
full dose of IMP, the dose can be reduced to half, i.e., 200 mg t.i.d., following discussion 
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 52 
08 JU
N 2020 with the CRO’s medical monitor. The patient must continue this dose for the remaining 
part of the study. If this dose is not tolerated, the IMP must be discontinued permanently. This sequence of events can be implemented only once for intolerable AEs within a given organ/body system. If the patient experiences a different intolerable adverse event within a different organ/body system, this sequence of events can be repeated for that AE.  
According to the FDA Guidance for Industry on Drug- Induced Liver Injury (DILI) ( 64), IMP 
must be permanently discontinued under circumstances related to elevated transaminases. IMP must also be discontinued for subjects with elevated transaminases 
where close observation (repeated laboratory tests) is not possible, see Section 6.5.2 
If in the Investigator’s judgement, a temporary halt in IMP is instituted because of elevated 
transaminases, a re- challenge must not occur if criteria described in Section  6.5.2 are 
met. 
7.8 Duration of Therapy 
Patients will receive the study medication for 20 months. 
7.9 Investigational Product Accountability 
Site Investigator  or pharmacist, or an approved representative, should maintain records 
of the product’s delivery to the study center , the inventory at the centre, the administration 
to each patient, and will ensure that all investigational products are stored in a secure, 
limited access area. These records should include dates, quantities, batch/serial numbers, expiration dates (if applicable), and the unique code numbers assigned to the investigational product(s) and study patients.   
A temperature log should also be kept  and should be made available when the monitors 
arrive on site or does remote monitoring.  
Investigators should maintain records that document adequately that the patients were administered the dose specified by the Protocol and reconcile all investigational product(s) received from the Sponsor.  
To ensure adequate records, all study treatments will be accounted for on an ongoing basis throughout the study in drug accountability forms at the study centre.   
Subjects will receive study medication at clinic visits at baseline, Months 1, 4, 8, 12 and 
16. Subjects will use a medication log and will be instructed to return all unused studymedication at each clinic visit. Compliance will be assessed by review of the medication
log at each visit and by documentation of unused study medication.  A subject who is not
adherent (taking less than 80% of assigned capsules) will be counseled at each visit onthe importance of taking IMP as instructed.
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 53 
08 JU
N 2020 8 STUDY PROCEDURES AND SCHEDULE  
8.1 Study Specifi c Procedures  
Please refer to the Schedule of Events in Table 2. 
8.1.1 Consent  
Patients will be given opportunity to read, ask questions, have those questions answered 
and sign the consent before any study procedures are performed. The consenting procedure must be documented.  
For competent trial subjects who have lost dexterity in the hands and cannot personally sign and date the informed consent form, an impartial witness signature may be used to document that the participant understands the study, the consent process, and has consented to continue to participate in the trial (if permitted by local regulations).  
8.1.2 Inclusion/Exclusion/Eligibility /Screen Failure  
Each patient must satisfy inclusion/exclusion criteria  and must be eligible for the study 
before they can be randomized.  Once a patient is randomized eligibility checks will not 
be repeated at the baseline visit.   
If a patient is found not to be eligible due to exclusion criteria # 2, 5, or 10, the specific eligibility criterion can be reassessed and out -of-range laboratory results can be redrawn 
within the 30- day screening window. For subjects outside of the screening window, 
rescreening is allowed only once and only if approved by the medical monitor. 
Rescre ening will be conditional on medical monitor approval if it is considered to be due 
to one of the following three reasons:  
•Subject failing to satisfy  exclusion criteria # 2, 5, or 10 which according to the
opinion of the medical monitor  is for an unrelated or reversible reason
•Out of window baseline visit
•If a concurrent medical condition in the opinion of the investigator requires initiation
of treatment or optimization of treatment. The subject can be rescreened when the
condition is stabilized.
8.1.3 Medical History I ncluding IBM history  
All past medical history that might affect the results of the study, such as muscle, bone, and degenerative disease that might affect performance on the outcome measures,  must 
be recorded. Information specific to IBM including date of onset and site of onset must be obtained.  
8.1.4 Physical Examination  
A general physical examination must be performed by a physician; in countries where accepted, this task can be delegated when documented on a delegation log.  
At months 3, 5 and 6 the physical examination may be conducted in a s hort-form. As a 
minimum, the e xamin ation must include assessments of right upper quadrant pain or 
tenderness  and rash.  
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 54 
08 JU
N 2020 8.1.5 IBM Functional Rating Scale  
The IBMFRS is a quickly administered (10- minute) ordinal rating scale used to determine 
participants' assessment of their capability and independence. It includes 10 measures 
(swallowing, handwriting, cutting food and handling utensils, fine motor tasks, dressing, 
hygiene, turning in bed and adjusting covers, changing position from sitting to standing, walking, and climbing stairs), graded on a Likert scale from 0 (being unable to perform) to 4 (normal). The sum of the 10 items gives a value between 0 and 40, with a higher score representing less functional limitation.  
8.1.6 Patient Global Impressions of Severity and Change  
The Patient Global Impression of Severity (PGIS) is a patient -reported assessment of the 
impact of IBM on a patient’s  ability to complete activities of daily living right now. The 
scale ranges from ‘none’ to ‘very mild,’ ‘mild,’ ‘moderate,’ ‘severe,’ and ‘very severe’ impact. The Patient Global Impression of Change (PGIC) is an assessment by the subject 
of self -perceived change in ability to conduct daily activities since the start of study 
medication. The scale ranges from ‘very much worse’ to ‘much worse,’ ‘a little worse,’ ‘no 
change,’ ‘a little improved,’ ‘much improved,’ and ‘very much improved’.  
8.1.7 Clinician Global Impressions of Severity and Change  
The Clinician Global Impression of  Severity (CGIS) is a clinician -reported assessment of 
the severity of the patient’s  IBM symptoms right now. The scale ranges from ‘none’ to 
‘very severe’. The Clinician Global Impression of Change (CGIC) is an assessment by the clinician of change in the patient’s IBM since the start of study medication. The scale 
ranges from ‘very much worse’ to ‘very much improved’.  
8.1.8 Muscle Strength Testing 
Muscle testing will be performed by three different methods. The first method is by Manual 
Muscle testing. 24 muscles will be tested. This method is routinely performed in a clinical 
setting and has been shown to be reliable.  
The second method involves using the MicroFET hand myometer. This is a hand- held 
device that allows the examiner to push against a muscle while the patient resist s. Unlike 
the manual muscle test which provides a range, this device will provide an actual number. 
One muscle group will be tested bilaterally (i.e., quadriceps).  Each muscle is tested twice 
while the patient is encouraged by the C linical Evaluator (CE)  to exert maximal effort. The 
maximum force generated by the patient from the two trials is used for each muscle group.  
The third strength method is the use of a Jamar Dynamometer that will measure grip 
strength. The maximum force generated by the patient from the two trials is used for each 
muscle group.  
8.1.9 Modified Timed Up and Go (mTUG)  
We will measure the patient’s ability to get up from a chair allowing participants  to use 
their arms (since most with sIBM cannot perform the ta sk without pushing off), walk 
3 meters, turn around and walk back to the chair and sit down. The use of nearby walls, 
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 55 
08 JU
N 2020 or assistance from a caregiver is not allowed. This test will be performed twice and the 
fastest time will be used in the data analysis.52,56  
8.1.10 6 Minute Walk Test w ith 2 Minute Distance Captured 
We will assess the distance IBM participants can walk in 6 minutes. Participants will be instructed to walk down one side of the track and back along the opposite side as quickly and safely as possible for 6 minutes. Participants will be allowed to take break as needed during the walking period, but timing will continued during breaks. Time to complete each 50- meter lap and distance walked in meters will be recorded after 
2 minutes and 6 minutes. We will capture use of assistive devices during the test.  
8.1.11 Falls Diary 
Each subject will record the number and date of falls and near falls within each month period.  
8.1.12 Health Assessment Questionnaire – Disability Index  (HAQ - DI) 
This is a self -report functional status (disability) measure based on the five 
patient -centered dimensions (death, disability, discomfort, drug toxicity and dollar 
costs).
57-58  
8.1.13 Columbia Suicide Severity Rating Scale  
The Columbia Suicide Severity Rating Scale (C -SSRS), will be administered to the 
subject by study personnel  at the screening visit using the “baseline/screening” version 
of the scale. The “since last visit” version will be administered at all other clinic visits. 
8.1.14 Vital Signs 
Vital signs, including weight, heart rate, respiratory rate, and sitting  blood pressure will 
be measured after the subject has been in a sitting position for 5 minutes. Temperature 
will also be measured. Any clinical significant abnormality must be reported as an AE.  
8.1.15 ECG  
A standard 12- lead ECG will be performed after the subject has been lying down for at 
least 5 minutes. All ECG recordings will be identified with the subject number, date, and time of the recording. The ECG interpretation will be recorded in the subject’s eCRF. Any abnorma lity at screening will be listed as medical history; any subsequent 
clinically significant abnormality must be reported as an AE.  
8.1.16 SF-36 
The Short Form -36 Health Survey is a 36- item, patient -reported survey of health. The 
SF-36 is a measure of health status.  
8.1.17 
Samples of 2 mL of serum  will be collected to obtain  levels. Serum  samples 
will be obtained, frozen at -70 degrees Celsius, and shipped. 
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 56 
08 JU
N 2020 8.1.18 Biobanking  
We will collect approximately 12 mL of blood at screening and approximately 6 mL of 
blood at M onths 4, 8,  12, and 20 for potential future testing.  
8.1.19 POP PK  
Samples of blood will be drawn as specified in the laboratory manual  at month 1 pre- dose 
and then 0.5 hours (+ 60 min)  post-dose, and month 8 pre- dose and then 1.5 hours (+ 60 
min) post -dose . A total of 4 samples per subject will be drawn; 2 samples at Month 1 and 
2 samples at Month 8. Patients will be asked to confirm the mode of administration (as 
per section 7.6) of the last dose taken at home before the POP PK blood draw.  
8.1.20 Laboratory Procedures/Evaluatio ns 
For each in -person visit, except for the Baseline visit, the following lab procedures will be 
performed:  
Hematology 
with differentials  hemoglobin; hematocrit; mean corpuscular volume (MCV); red blood cells ( RBC/ erythrocytes); white blood cells 
(WBC/ leukocytes); and differential count (basophils, eosinophils, 
lymphocytes, monocytes, neutrophils  [% and absolute count ], and 
platelets)  
Biochemistry  albumin; alkaline phosphatase; alanine aminotransferase (ALT/SGPT); aspartate aminotransferase ( AST/SGOT); bilirubin 
(total); calcium; chloride; cholesterol; creatine kinase ); creatinine; 
gamma- glutamyl transferase (GGT); glucose (random); iron; 
lactate dehydrogenase (LDH); phosphate; potassium; protein total; sodium; triglycerides ; BUN; uric acid  
Other  cystatin C  
A urine pregnancy test will be performed on women of childbearing potential before the study medication is given to them at baseline and at each visit.  
All laboratory results must be signed and dated by the physician in a timely manner. All abnormal results will be classified as either clinically significant or not clinically significant. 
All clinically significant abnormal values must be recorded as medical history or A Es, as 
appropriate. All of the above mentioned labo ratory tests will be performed by a central 
laboratory .  
If the subject cannot attend the trial site for specific laboratory follow -up, the analyses 
may be conducted at a local laboratory.  For guidance on follow -up of specific laboratory 
abnormalities, see section 9.6  
8.1.20.1 Specimen Preparation, Handling and Shipment  
All laboratory samples will be handled and shipped as per the Central Laboratory Manual . 
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 57 
08 JU
N 2020 8.2 S tudy Schedule 
This study is co- funded by a 4- year FDA -OPD grant  and Orphazyme. We anticipate 
approximately 15 months of active screening and enrollment, and 21 months of treatment 
and follow -up. 
The planned sequence and maximum duration of the trial periods will be as follows:  
1.Screening: up to 1 month
2.Treatment: 20 months
3.Post-treatment Follow -up Call: 1 month after last dose of IMP
The maximum treatment duration for each subject is approximately 20 months.
The maximum trial duration for each subject is approximately 22 months.Following the screening and baseline visits, Visits 3 to 7 are to occur every 30 day s 
(± 7 days) and the remaining visits are to occur every 60 days relative to baseline 
(± 7 days). In- person follow up visits at the trial site are to occur at Months 1, 2, 3, 4, 5, 6, 
8, 12, 16, and 20. Phone calls will be made at Months 10, 14, 18, and 21. If a patient must 
stop the trial medication for any reason, every effort will be made to have the patient participate in each subsequent visit as scheduled.  
8.2.1 S creening (30 D ay Window)  (Visit 1)  
The subject must be screened within 30 days before enrollment in the trial. The following 
procedures will be performed at screening:  
•Obtain written informed consent and/or assent.
•Assess inclusion/exclusion criteria.
•Collect demographic information.
•Record IBM history and medical history, including current therapies (e .g.,
prescription and nonprescription medications).
•Perform a physical examination.
•Measure vital signs, including weight, pulse, sitting  blood pressure, respiratory
rate, and temperature.
•Perform a 12- lead ECG.
•Collect blood for safety laboratory tests, anti -  levels, and biobanking. 
•Complete the C -SSRS “baseline/screening” (lifetime) assessment.
8.2.1.1 Randomization 
The site investigator will review and sign off on all inclusion and exclusion criteria and safety laboratory tests prior to randomization.  Completeness of eCRF and safety 
laboratory data will be reviewed by the KUMC project manager (or delegate) before  
randomization can occur  as detailed in Section 7.  
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 58 
08 JU
N 2020 8.2.2 Baseline (Visit 2, Day 1) 
The following procedures will be performed at Visit 2 (baseline):  
•Measure vital signs, including weight.
•Perform a urine pregnancy test for female subjects of childbearing potential.
•Record concomitant medications and concomitant therapies.
•Assess and record AEs occurring since signing of informed consent .
•Complete the PGIS,  IBMFRS, MMT, MVICT of quadriceps and grip, mTUG, grip
assessments, 6 minute walk test with 2 minute distance, HAQ -DI, SF -36, and
CGIS .
•Administer the first dose of IMP and observe for 1 hour after the dose.
•Dispense IMP for the initial one- month period, and give the patient instructions
regarding dosing schedule and trial requirements.
•Provide the subject with a falls diary.
•Remind patient not to take the morning dose of the study medication on the day of
the Month 1 visit (to allow for pre -dose PK blood sampling).
8.2.3 O ngoing Treatment Visits (Visits 3 to 13, Months 1 to 18)  
8.2.3.1 Months 1 and 2 
The following procedures will be performed at the site visit s at Month s 1 and 2: 
•At Month 1 only , to enable a pre- dose PK sample, the patient must not  have taken
study medication approximately 8 hours prior to the site visit.
•Measure vital signs, including weight.
•Perform a physical examination.
•Collect blood for clinical safety laboratory tests and (at Month 1 only) for PK
(pre-dose) .
•At Month 1 only,  the patient takes dose of study medication in the clinic.
•At Month 1 only, collect blood for PK 0.5 hours post -dose as per protocol section
8.1.19.
•Record concomitant medications and concomitant therapies.
•Assess and record AEs occurring since the last evaluation.  Follow up ongoing AEs .
•Complete the IBMFRS.
•Complete the C -SSRS (“since last visit” ass essment).
•Perform a urine pregnancy test for female subjects of childbearing potential.
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 59 
08 JU
N 2020 •At Month 1 only, collect empty IMP packaging and unused IMP, and dispense
additional IMP.
•Collect and review the falls diary and give the subject a new falls diary.
8.2.3.2 Months 3, 5, and 6 
The following procedures will be performed at the site visits at Months 3 , 5 and 6:  
•Collect blood for clinical safety laboratory tests
•Record concomitant medications and concomitant therapies.
•Perform a physical examination.
•Assess and record AEs occurring since the last evaluation. Follow up ongoing AEs.
•At Month 3 and 6 only , complete the IBMFRS
•Complete the C -SSRS (“since last visit” assessment).
8.2.3.3 Months 4, 8, 12, and 16 
The following procedures will be performed at the site visits at Months 4, 8, 12, and 16:  
•At Month 8 only, to enable a pre- dose PK sample, the patient must not have
taken study medication approximately 8 hours prior to the site visit.
•Measure vital signs, including weight.
•Perform a 12- lead ECG (Month 12 only).
•Perform a physical examination.
•Collect blood for clinical safety laboratory tests, anti -  levels (Month 12 
only), biobanking (Months 4, 8, and 12 only), and PK (Month 8 only ; pre-dose).  
•At Month 8 only; t he patient takes dose of study medication in the clinic.
•At Month 8 only; collect blood for PK 1.5 hours post -dose as per protocol section
8.1.19.
•Record concomitant medications and concomitant therapies.
•Assess and record AEs occurring since the last evaluation.  Follow up ongoing AEs .
•Complete the PGIS, PGIC, IBMFRS, MMT, MVICT of quadriceps and grip, mTUG,grip assessments, 6 minute walk test with 2 minute distance, HAQ -DI, SF -36,
CGIS , and CGIC .
•Complete the C -SSRS (“since last visit” assessment).
•Collect empty IMP packaging and unused IMP, and dispense additional IMP.
•Perform a urine pregnancy test for female subjects of childbearing potential.
•Collect and review the falls diary and give the subject a new falls diary.
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 60 
08 JU
N 2020 8.2.3.4 Months 10,  14, and 18 
The following procedures will be performed at the telephone visits at Months, 10, 14, 
and 18: 
•Record concomitant medications and concomitant therapies.
•Assess and record AEs occurring since the last evaluation.
•Complete the IBMFRS.
•Ensure the subject has sufficient IMP and arrange for additional IMP supplies if
needed.
•Review the falls diary.
8.2.4 Final In- person Study Visit and Follow- Up Phone Call  
The following procedures will be performed at the final in- person trial visit at Month 20:  
•Measure vital signs, including weight.
•Perform a 12- lead ECG (Month 2 0 only).
•Perform a physical examination.
•Collect blood for safety laboratory tests, anti -  levels, and biobanking.  
•Record concomitant medications and concomitant therapies.
•Assess and record AEs occurring since the last evaluation.
•Perform a urine pregnancy test for female subjects of childbearing potential.
•Complete the PGIS, PGIC, IBMFRS, MMT, MVICT of quadriceps and grip, mTUG,grip assessments, 6 minute walk test with 2 minute distance, HAQ -DI, SF -36,
CGIS , and CGIC .
•Complete the C -SSRS (“since last visit” assessment).
•Collect empty IMP packaging and unused IMP.
•Collect and review the falls diary.
Upon completion of this study, qualified patients may provide informed consent and enter 
an open- label extension study at the Month 20 visit. Assessments recorded at this visit 
will also constitute the first assessments of such  open- label extension study.  
The following procedures will be performed at the final telephone visit at Month 2 1: 
•Record updates to any concomitant medications or therapies that were ongoing atthe previous visit.
•Record updates to any AEs that were ongoing at the previous visit.
•Reco rd any new SAEs.
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 61 
08 JU
N 2020 8.2.5 Early Termination V isit 
If the patient wishes to withdraw from the study and they do not wish to continue in the 
study visits (see Section 6.5.2) , you must bring them in for the Month 20 (Visit 14) study 
procedures. This will need to be followed by the visit 15 (30 day post -visit) phone call.  
8.2.6 Unscheduled Visits  
Unscheduled visits to evaluate potential adverse events can occur at any time. Vital signs, physical examinations, safety laboratory,  C-SSRS,  adverse events and concomitant 
medications will be collected during this visit. If this visit is greater than 1 week before their regularly scheduled appointment, they must also attend the regularly scheduled 
appointment. Unscheduled visits that are solely for the purpose of refilling medication do 
not require any of the safety assessments.  
8.2.7 Exceptional Circumstances Preventing Patient From Attending In- Person Visits  
In the exceptional circumstance that a patient cannot attend a scheduled or an 
unschedu led visit at the site information about adverse event s, concomitant medication s 
and IBMFRS can be obtained via telephone. Such an exceptional circumstance s hould 
be discussed with the CRO’s medical monitor .  
CONFIDENTIAL
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 63 
08 JU
N 2020 8.3 Concomitant Medications, Treatments, and Procedures 
Concomitant medication use, including over -the-counter supplements, will be 
documented throughout the study. The entry will include the dose, regimen, route, 
indication, and dates of use. Antioxidants and vitamins will be allowed. There may be soreness from the strength and functional tests that the patients must undergo.  
Concomitant procedures (e.g. ultrasound investigation of the liver) must be recorded in the CRF.  
8.4 Precautionary Medications, Treatments, and Procedures  
Arimoclomol is an in vitro inhibitor of the OCT2, MATE -1, and MATE -2K transporters and 
consequently may inhibit the elimination of cationic drugs that are significantly eliminated by tubular secretion. In addition, arimoclomol is an in vitro substrate of the MATE -1 and 
MATE- 2K transporters. Arimoclomol undergoes renal tubular secretion, and concomitant 
treatment with drugs that are MATE -1 or MATE -2K inhibitors may therefore lead to 
increased exposure of arimoclomol. Consequently, the concomitant use of cationic drugs that are significantly eliminated by tubular secretion as well as drugs that are MATE -1 or 
MATE- 2K inhibitors should be administered with caution. These include, but are not 
limited to , amantadine, amiloride, cimetidine, dopamine, famotidine, memantine, 
metformin, pindolol, procainamide, ranitidine, varenicline, oxaliplatin, dofetelide, trimethoprim, quinidine, verapamil, levofloxacin, ciprofloxacin, moxifloxacin, pyrimethamine, and ondansetron.  
Addi
tionally, in vitro studies show that arimoclomol is a direct inhibitor of CYP2D6 and 
may potentially cause increase in exposure of co- administered medications that are 
substrates of CYP2D6 when arimoclomol is dosed at 400 mg t.i.d.   
Since, t he magnitude of the potential increase cannot be predicted from in vitro data 
caution is advised if arimoclomol is co- administered with medicinal products that are 
metabolised by CYP2D6. This may for examples be relevant for class I anti -arrhytmics, 
tricyclic antidepressants and selective serotonin reuptake inhibitors (SSRI’s)  particularly if they are known to be sensitive and moderate sensitive CYP2D6 substrates and/or have a narrow therapeutic index.  
The product information for co- administered medicinal  products should be consulted for 
guidance on concomitant treatment with a CYP2D6 inhibitor as dose adjustment of the 
CYP2D6 substrate may be appropriate. For compounds metabolised by CYP2D6 the dose may be reduced and for pro- drugs that are converted to the active compound by 
CYP2D6 the dose may be increased to ensure efficacy.  
Animal studies have indicated a possible interaction with furosemide (additive effect) and enalapril (decreased effect), both at high doses, and consequently concomitant dosing should be done with caution.  
8.4.1 Prohibited Medications, Treatments, and Procedures 
The following medications are prohibited during the study and for specified durations prior to enrollment as noted in the exclusion criteria:  
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 64 
08 JU
N 2020 •Use of testosterone except as allowed in the exclusion criteria.
•Canna
bis except as allowed in the exclusion criteria.
•Pr
ednisone, IVIg, or other immunosuppressants except as allowed in the exclusion
criteria. A short course [up to 4  weeks] of systemic treatment with prednisolone
>7.5 mg or  equivalent is allowed for conditions not related to IBM (e.g. due to an
asthma attack). Topical, nasal, and ocular corticosteroids are allowed unless they
are being widely applied or the severity of the underlying condition makes themunsuitable in the Investigator’s opinion. Local steroid injections are allowed.
•Othe
r experimental treatments
Shou
ld there become a medication, treatment , or procedure that is either precautionary 
or prohibited, all patients will be notified immediately. IRB/IEC’s will be notified as soon as possible ; also include any IMP or any product not approved by the European Medicines 
Agency (EMA) or the United States Food and Drug Administration.  
8.4.2 Prophylactic Medications, Treatments, and Procedures 
There may be soreness from the strength and functional tests that the patients must undergo. They may take normal prophylactic medications, treatments or procedures to ease the soreness.  
8.4.3 Rescue Medications, Treatments, and Procedures  
Currently there are no rescue medications, treatments and procedures to treat IBM.  
8.4.4 Participant Access to Study Drug At Study Closure 
Upon completion of this study, qualified patients may provide informed consent and enter an open- label extension study . 
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 65 
08 JU
N 2020 9 ASSESSMENT OF SAFETY 
9.1 Adverse Events 
9.1.1 Adverse Event Definition 
An AE is defined as: Any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.  
An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.  
An AE can also refer to an untoward response to the administration of the IMP, but can also occur as a result of the protocol -required procedures or be unrelated to both and 
include worsening of pre- existing conditions, for example.  
AEs include the following: 
•Suspected adverse medication reactions;
•Reactions from medication overdose, abuse, sensitivity, or toxicity;
•Apparently unrelated illnesses, including the worsening of a pre- existing illness;
•Injury or accidents;
Not
e: If a documented medical condition is known to have caused the injury or accident, 
only the accident should be reported as an AE;  
•New or aggravated clinically relevant abnormal medical finding at a physical
examination as compared with previous assessments;
•Laboratory abnormalities or other abnormal assessments (e.g. physical examination,
vital signs, ECG) that require clinical intervention or further investigation (beyondordering a repeat [confirmatory] test) unless they are associated with an alreadyreported clinical event.
9.1.2 Definition of a Serious Adverse Event  
A serious adverse event (SAE) is defined as any untoward medical occurrence that: 
•Results in death;
Note : Death is an outcome of an AE, and not an AE in itself. Event which led to death
should be recorded with fatal outcome. In reports of death due to “Disease
Progression”, where no other information is provided, the death will be assumed tohave resulted from progression of the disease under investigation.
All deaths occurring on the study or patient withdrawal must be reported.
•Is life -threatening;
A life -threatening event places the patient at risk of death at the time of the event. It
does not refer to  an event which hypothetically might have caused death if it were
more severe).
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 66 
08 JU
N 2020 •Requires inpatient hospitalization or prolongation of existing hospitalization;
Note : In general, hospitalization signifies that the patient has been detained (usually
involving at least an overnight stay) at the hospital or emergency ward for observation
and/or treatment that would not have been appropriate in the physician’s office oroutpatient setting. Complications that occur during hospitalization are AEs.  If a
complication prolongs hospitalization or fulfils any other serious criteria, the event isserious. When in doubt as to whether other events meet the serious criteria, the eventis to be considered serious. When in doubt as to whether “hospitalization” occurredor was necessary, the AE should be considered serious.  Hospitali zation for elective
treatment of a pre- existing condition that did not worsen from baseline is not
considered an AE.
•Results in persistent or significant disability/incapacity;
Note: The term “significant disability” means a substantial disruption of a person’s
ability to conduct normal life functions. This definition is not intended to includeexperiences of relatively minor medical significance such as uncomplicatedheadache, nausea, vomiting, hospital, influenza, and accidental trauma (e.g.,sprained ankle) which may interfere or prevent everyday life functions, but do notconstitute a substantial disruption.
•Is a congenital anomaly/birth defect;
•Is an important medical event(s) that may not be immediately life threatening or resultin death or hospitalization but that may jeopardize the patient or require interventionto prevent one of the above outcomes. Examples of such events are intensivetreatment in an emergency room or at home for allergic bronchospasm; blooddyscrasias or convulsions that do not result in hospitalization; or development of drugdependency or drug abuse. Medical and scientific judgement should be exercised indeciding whether expedited reporting is appropriate in such circumstances.
9.2 Recording and Reporting of Adverse Events 
All AEs and SAEs, as defined above, encountered during the clinical study will be reported in the appropriate section of the CRF. Information will include the following:  
•Duration of the AE (onset/resolution dates);
•Relationship to the IMP (refer to Section 9.2.2 );
•Severity (refer to Section 9.2);
•Concomitant therapy given (or other action taken);
•Action taken with respect to the IMP.
If an AE increases in severity it will be recorded as a new record with the same AE identifier.  
AE data should be obtained through observation of the patient, from any information 
volunteered by the patient and through patient questioning. The patient may be asked 
“Do you have any health problems?” or “Have you had any health problems since your last site visit?”  
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 67 
08 JU
N 2020 Reporting of Signs and Symptoms versus a Diagnosis 
Recording a diagnosis (when possible) is preferred to recording a list of associated signs and symptoms. However, if a diagnosis is known but there are associated signs or symptoms not generally attributed to the diagnosis, the diagnosis and each sign or symptom must be recorded separately.  
Pregnancy Should a pregnancy occur in a female patient or the partner of a male patient, it must be reported promptly, within 24 hours of the site first becoming aware of the pregnancy, by 
entering the pregnancy as a non -serious AE in the CRF  and completing, signing, and 
dating the pregnancy report form. The pregnancy report form should be sent to the safety 
vendor    using the contact details in Section 9.2.3. A pregnant patient should discontinue 
treatment, but remain in the study for ongoing assessments unt il the birth of the baby . 
9.2.1 Definition of Severity of Adverse Events  
Severity of any AE will be graded using the definitions below. 
Definition of Severity 
of Adverse Events  
Mild Does not interfere with patient’s usual function (awareness 
of symptoms or signs, but easily tolerated [acceptable]).  
Moderate Interferes to some extent with patient’s usual function (enough discomfort to interfere with usual activity 
[disturbing])  
Severe Interferes significantly with patient’s usual function 
(incapacity to work or to do usual activities [unacceptable]). 
Note: Severe is a measure of intensity whereas an event must meet one of the criteria for serious events listed in Section 9.1.2 to be considered serious; thus, a severe 
reaction is not necessarily a serious reaction. For example, a headache may be severe 
in intensity, but would not be classified as serious unless it met one of the criteria for serious events listed in Section 9.1.2. An AE that is assessed as severe should not be confused with a SAE.  
9.2.2 Definition of Relationship of AEs to a Medicinal Product and/or Study Procedure 
Site Investigator must assess the possible relationship between the AE and the IMP  and 
record that assessment in the CRF.  
The Sponsor will evaluate all SAEs with respect to expectedness according to the IB.  
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 68 
08 JU
N 2020 The relationship should be assessed according to the criteria below: 
Probably Related AEs that are temporally linked and for 
which the study product is more likely to be 
the explanation than other causes, which 
may impro ve when not using study product 
Possibly Related AEs that could equally well be explained by 
study product or other causes, which are usually temporally linked and may improve when not using study product but do not 
reappear when using study product  
Not Related AEs that can be clearly explained by 
extraneous causes and for which there is no plausible association with study product, or AEs for which there is no temporal 
relationship  
9.2.
3 SAE Reporting Procedure for Site Investigators 
The Investigator must report (by fax or email) all SAEs to the safety vendor  within 24 
hours of awareness of an SAE by completing, signing and dating the Serious Adverse Event Report Form, verifying the accuracy of the information recorded in the form  with 
the source documents and CRF, and sending the SAE form to the safety vendor  by one 
of the following methods:  
Study Contact for Reporting Serious Adverse Events 
Please r
efer to the SAE Reporting Contact Details  document . 
If
, for any reason, it is not possible to complete all sections of the SAE form withi n 
24 hours, transmission of the form must not be delayed and the outstanding information 
should be sent on a follow -up SAE form.  
Information on SAEs will be recorded on a SAE form. Blank copies are included in the study Investigator’s f ile.  
The SAE form must be completed as fully as possible with information relevant to the SAE(s) being reported. All fields should be populated or marked accordingly if no information is available.  
The investigator is required to comply with applicable regulations (including local laws and guidances) regarding the notification of his or her health authorities, IRB/IEC, principal and coordinating investigators, trial investigators, and institutions. Each investigator is obligated to learn about the reporting requirements for investigators in his/her country.  
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 69 
08 JU
N 2020 9.2.4 Follow- up SAE Reports 
For all SAEs where important or relevant information is missing, active follow- up should 
be undertaken. The follow -up information must be presented on an SAE form marked as 
follow- up. It is necessary only to provide the new information, together with the following 
minimal information (initial report, adverse event, date of occurrence, subject identification 
(ID), study ID, IMP, and site number); this will allow the follow -up information to be linked 
to the initial SAE report, with the SAE form signed by an Investigator.  
Specific information may be requested by the safety vendor using a follow -up request 
form.  
Investigators or other site personnel should send relevant or requested anonymiz ed 
supporting documentation (e.g. ECG, laboratory results, autopsy report) to the safety 
vendor .  
The Investigator will ensure that all the necessary information is provided within the timelines stipulated by  the safety vendor  when the request for information is made.  
Follow- up reports (as many as required) should be completed and submitted following 
the same procedure above.  
9.3 Reporting Serious Adverse Events to the IEC/IRB 
The Investigator is responsible for informing local IECs/IRBs of the applicable safety 
reports in compliance with local regulations. Copies of all correspondence relating to reporting of any safety reports to the IEC/IRB should be maintained in the Investigator’s files and provided to Premier Research.  
9.4 Reporting of Suspected Unexpected Serious Adverse Reactions (SUSARs) 
A suspected unexpected serious adverse reaction (SUSAR) is an SAE, the nature or 
severity of which is not consistent with the reference safety information of the study drug 
in the IB and for which there is at least a reasonable possibility of a causal relationship with the study drug.  
The Sponsor shall ensure that all relevant information about SUSARs that are fatal or life-threatening is recorded and reported as soon as possible to the concerned authorities, 
central IECs/IRBs and Investigators, and in any  case no later than seven days after 
knowledge by the Sponsor of such a case, and that relevant follow -up information is 
subsequently communicated within an additional eight days.  
All other SUSARs shall be reported to the concerned authorities, central IE Cs/IRBs and 
Investigators as soon as possible but within a maximum of fifteen days of first knowledge by the Sponsor. The Sponsor will report all SUSARs via FDA, the EudraVigilance Clinical 
Trials (CT) Module or Council for International Organizations of Medical Sciences (CIOMS) forms.  
The Investigator is responsible for informing local IECs/IRBs of the applicable safety reports in compliance with local regulations. Copies of all correspondence relating to reporting of any safety reports to the IEC/IRB should be maintained in the Investigator’s files and provided to Premier Research. 
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 70 
08 JU
N 2020 9.5 Adverse Event Reporting Period 
AEs will be collected from the time of written informed consent until the end of the trial or 
patient withdrawal. All ongoing AEs will be followed until the follow -up telephone visit and 
SAEs will be followed up until resolution, until the condition stabilizes, until the event is otherwise explained, or until the patient is lost to follow -up, whichever occurs first.  
Any increase in transaminases > 3x ULN  will be followed up (see section 9.6.2) until the 
the values have stabelised or the baseline level of the patient has  been reestablished.  
Any SAE (including an AE that leads to death) that occurs after the end of the trial, which the Investigator assesses as related to a trial procedure and/or medicinal product, should also be reported.  
All new AEs or the worsening of any ongoing events from the time of informed consent will be r ecorded on the AE pages of the CRF.  
9.6 Follow -up for specific laboratory abnormalities  
9.6.1 Increased serum creatinine  
Serum creatinine values > 2- 3 fold compared to the patient’s baseline value should be 
further investigated for signs of kidney injury. Estimation of the patient’s GFR based on BUN, creatinine, and cystatin C should be performed. In addition, follow -up should be 
done according to local hospital guideline. Follow -up may include measurement of 
oliguria, urine analysis, glomerular filtration rate, vital signs, ultrasound of the kidney, blood sampling for parathyroid hormone, metabolic status, and investigation of other marker s of kidney dysfunction and alternative causes of increased creatinine.  
9.6.2 Increased transaminases  
Transaminases (AST, ALT) > 3 x ULN must be further investigated in line with the FDA Guidance on Drug- Induced Liver Injury ( 64).  
IBM patients may exhibit elevation in transaminases,  and according to exclusion criteria 
11, subjects are only excluded with clinically significant hepatic disease indicated by 
clinical laboratory assessment (results ≥3 times the upper limit of normal [ULN] for alanine aminotransferase combined with bilirubin ≥2 times the ULN . A consequence of this criteria 
is that  subjects with ALT elevation not  in the presence of bilirubin elevation may be eligible 
for the trial.  
The investigator may apply clinical judgement to the threshold of transaminases that 
qualify for close monitoring. T his will be  based on the subject’s baseline clinical safety 
laboratory results and the expected variability of such parameters under repeat measure.  
Exceptions  to the guidance for close monitoring must be discussed with the medical 
monitor and the rationale behind any clinical judgement overruling the below definitions must be documented in the subjects medical/source records.  Note that investigator 
judgment may not be applied to the guidance regarding IMP interruption or discontinuation (see Section 6.5.2).  
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 71 
08 JU
N 2020 Upon first observation of transaminases (AST, ALT) > 3 x ULN, a repeat test must be 
performed within 48- 72 hours (ALT, AST, ALP, bilirubin) and the subject should be 
enquired for presence of symptoms (fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, or rash).  
If the increase is confirmed, close observation must be performed:  
•Repeating of ALT, AST, ALP, GGT, bilirubin, eosinophils (differential count) 2- 3
times weekly. Frequency of retesting may be decreased to once a week or less(after agreement with the medical monitor) if abnormalities stabilize or the trial drughas been discontinued and the subject is asymptomatic.  The v alues should be
monitored until the values have stabelised or the baseline level of the patient has
been re- established.
•Obtaining/confirming detailed history of symptoms and prior or concurrent
diseases.
•Obtaining/confirming concomitant drug use (including nonprescription medications
and herbal and dietary supplement preparations), alcohol use, recreational druguse, and special diets.
•Ruling out acute viral hepatitis types A, B, C, D,  and E; autoimmune or alcoholic
hepatitis; NASH; hypoxic/ischemic hepatopathy; and biliary tract disease (e.g.
performing an abdominal ultrasound or Magnetic resonance
cholangiopancreatography (MRCP)).
•Obtaining a history of exposure to environmental chemical agents.
•Obtaining additional tests to evaluate liver function, as appropriate (e.g., INR,direct bilirubin).
•Considering gastroenterology or hepatology consultations.
If
 close observation is not possible, IMP must be interrupted or discontinued (see s ection 
6.5.2.2) 
If the subject cannot attend the trial site for close monitoring, the analyses may be 
conducted at a local laboratory.  
At the earliest possible opportunity, a single serum sample should be taken for use in case further analyses to explore possible mechanisms behind the transaminase elevations are conducted.  
The sample may be processed and shipped under ambient or frozen conditions and will 
be stored frozen at the central laboratory. This sample will be discarded as soon as it is decided that such analyses are not warranted or after sample processing and analysis is completed which will be no longer than 2 years after the completion of the trial.  
All local laboratory assessments and other assessment performed in relation to increased transaminases must be recorded in the CRF including the appropriate reference ranges.  
For scenarios where a permanent halt in the IMP is required, see Section 6.5.2.2 
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 72 
08 JU
N 2020 9.7
 Study Halting Rules 
All attempts will be made to enhance patient com pliance (see Section 7.9). Early 
withdrawal may occur for any of the reasons  listed in Section 6.5.1.  
If the patient needs to discontinue study medication, every effort will be made to 
encourage the patient to continue with the study  visits until study completion.  If a patient 
is unable to return to the center, a phone call will be made to the patient. In the event of a loss to follow -up, information about the patient will be sought from  the family or family 
physician.  
9.8 Study Discontinuation 
Please see Section 6.5.2. 
9.9 Safety Oversight  
The Premier Research medical monitor will be responsible for independent review of the 
safety laboratory tests and adverse events , will be resp onsible for monitoring the real -time 
reporting of SAEs, and will review laboratory reports and adverse events monthly, or more 
frequently as needed. The medical monitor will be blinded to treatment assignment. If the 
medical monitor has concerns regarding the safety data, they may notify the DMC. The 
medical monitor may request additional or clarifying information from the coordinating center of the treating physician. The medical monitor will prepare a report to present to 
the DMC prior to their meetings.  
9.10 Data Monitoring Committee  
A DMC will assess safety and tolerability at regular intervals .  The responsibilities of the 
DMC are further described in a DMC charter . 
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 73 
08 JU
N 2020 10 CL INICA L MON ITOR ING 
Premier Research is  responsible for ensuring the proper conduct of the clinical trial with 
regard to protocol adherence and validity of the data recorded in the CRFs.  Premier 
Research will conduct site visits to monitor the trial and ensure compliance with the 
protocol, GCP,  and applicable regulations and guidelines. The assigned clinical research 
associate(s) will visit the investigator and trial site at periodic intervals and maintain periodic communication.  
The si
te Investigator will be informed of anticipated in -person monitoring visits. He/she 
will also receive a notification prior to each monitoring visit during the course of the study. It is expected that the Investigator and/or his/her Sub- investigator(s) and other 
appropriate staff will be available on the day of the visit to discuss study conduct.  
For addi
tional information, please refer to the clinical monitoring plan.  
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 74 
08 JU
N 2020 11 STATISTICAL CONSIDERATIONS 
11.1 General Consider ations  
This section presents a summary of the planned statistical analyses. A statistical analysis 
plan (SAP) that describes the details of the analyses to be conducted will be written prior to database lock.  
Unless otherwise indicated, a two- sided significance level of 5% will be used for all 
hypothesis testing.  
Every effort will be made to retain subjects in this trial, to promote adherence to the study 
protocol, and to collect all data at every visit. If a subject cannot tolerate (even after tapering down) or refuses to continue taking study medication, we will continue to follow 
and evaluate that subject.  If a subject withdraws from the trial, attempts will be made to 
bring the subject in for a final evaluation. Compliance with trial procedures, subject disposition, and reasons for subject withdrawal will be carefully tracked throughout the study.  
11.2 Statistical Hypotheses 
The primary outcome variable is the change from baseline to Month 20 in the total score 
on the IBMFRS. The null hypothesis to be tested is that the mean value of this outcome 
variable is the same in the arimoclomol and placebo groups.  The alternative hypothesis 
is that the mean value differs between the groups (two- sided).  
11.3
 Analysis Populations 
The following analysis populations are planned for this trial: 
•Intent -To-Treat Population (ITT)  or Full analysis set (FAS ): The ITT/FAS
population includes all randomized patients. Patients in the ITT population willcontribute to the evaluation ‘as randomized’.
•Safety Population (SAF):  The SAF population includes all patients who receive
any amount of trial medication. Patients in the SAF population will be analysedaccording to treatment actually received. The definition of “ actually received” will
be based on simple couting the number of days on either of the two treatments.
Further detail s will be provided in the SAP.
11.4
 Description of Statistical Methods  
11.4.1 Baseline Descriptive Statistics  
The distributions of demographic and clinical characteristics will be described for the treatment groups as well as the overall cohort using standard summary statistics.  
11.4.2 Analysis of the Primary Efficacy Endpoint(s)  
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 75 
08 JU
N 2020 Analysis of the Primary Estimand 
The analyses will be based on the FAS using all observations from schedueld visits (see 
SAP for details)  regardless of treatment adherence and used of concomittant medication. 
The analysis is a Mixed Model for Repeated Measurements (MMRM). The independent 
effects included in the model are treatment interacting with visit, trial centre as a separate main effect and baseline IBMFRS interacting with visit. An unstructured covariance matrix 
for IBMFRS measurements within the same patient will be used, hereby assuming that measurements from different subjects are conditionally independent.  
The MMRM is a well -established method that accounts for the uncertainty pertaining to 
missing data. The model assumed that data are missing at random (MAR). Under this assumption, the statistical behaviour of the missing data can be described by the observed data included in the model, thus, observed IBMFRS responses at all visits and the observed effects adjusted for in the model. Consequently, MAR will reflect adherence to protocol (not nessesarily adherence to treatment). Of note, an analysis based on MAR may attribute benefits to patients who withdraw from trial altogether regardless of the reason for discontinuation. By assuming MAR but allowing patients to remain under 
observation while no longer exposed to trial IMP means that the primary statistical analysis evaluates effectiveness of arimoclomol, thus targeting the primary estimand.  
The null hypothesis to be tested is that the mean difference in the primary endpoint between arimoclomol and placebo is zero. The alternative hypothesis is that it differs from zero. If the null -hypothesis is rejected (two- sided p- value < 0.05), and if the estimated 
mean difference in the primary endpoint between arimoclomol and placebo is greater than zero, then the primary objective of the trial will be confirmed.  
The analysis of the primary estimand and other meth ods for handling missing data 
(including imputation models) are further  specified in the SAP.  
Anal
ysis of the Secondary Estimand 
The change from baseline in IBMFRS total score will be assessed for the secondary estimand using an MMRM analysis  like the one detailed above. The difference lie in the 
data used for analysis: This  MMRM will be based on all observed IBMFRS -data from 
scheduled visits while patients were exposed to trial mediction (i.e. before treatment 
discontinuation (see SAP for further details)) . 
Expl
orative analysis 
To explore the IBMFRS in further details , indiviual items and domains will be presented 
based on both in- clinic and telephone assessments . The planned analysis is further 
specificed in the SAP.  
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 76 
08 JU
N 2020 11.4.3 Analysis of the Secondary Endpoint(s)  
The secondary outcome variables of efficacy including; 6MWT distance walked (at 
minutes 2 and 6) strength outcomes (quantitative quadriceps strength and MMT scores, 
grip strength), HAQ -DI, SF -36 scores, falls and near falls, CGIS, CGI C, PGIS, PGIC, and 
modified timed up and go (mTUG) will be analysed at month  12 and 20 for both the 
primary and secondary estimands. Further details on the analysis methods wil be 
provided in the SAP.  
11.5
 Safety Analyses  
Adverse events will be summarized by treatment group, maximum severity, and perceived relationship to study medication.  
Continuous measures of safety (vital signs, laboratory test results) will be presented using 
descriptive statistics and the C -SSRS will be summarized . 
See the SAP for the full specification of the safety and tolerability analysis.  
11.6 Adherence and Retention Analyses  
Compliance data (pill counts) will be summarized by treatment group, overall and by visit. 
Subject disposition (study completion, study completion on a reduced dosage or off of study drug, withdrawal) will also be summarized by treatment group.  
11.7
 Planned Analyses 
11.7.1 Safety Review  
The sponsor will monitor blinded safety data on an ongoing basis and the DMC will monitor safety an d tolerability according the DMC charter.  
11.7.2 Additional Sub -Group Analyses  
We will investigate the interactions between treatment group and selected baseline variables including site, IBMFRS score, 6- minute walk test distance, site of onset, and 
 status. This will be done by adding the appropriate main effect and interaction 
terms to the primary analysis model. Since the power to detect potentially meaningful interactions will be limited, the magnitudes of treatment effects in the relevant subgroups will b e ex amined.  The observation of clinically important subgroup differences in 
treatment effects (e.g., in those with low vs. high IBMFRS scores at baseline) will serve as hypothesis generation for possible future studies designed to specifically address the issue of differential therapeutic response.  
11.7.3 Sensitivity Analyses  
To investigate the sensitivity of the primary and secondary analysis results, complementary and 
separate analyses will be performed for each of the two estimand s. In particular. these sensiti vity 
analyses will be used to evaluate the sensitivity of the results due to the impact of missing data . 
Further details are provided in the SAP. 
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 77 
08 JU
N 2020 11.8
 Sample Size Considerations 
The primary outcome variable is the change from baseline to Month 20 in the IBMFRS.  
In the arimoclomol pilot study, the standard deviation of the 12- month change  in IBMFRS 
was 2.9.  The mean change in the placebo group was - 3.5 and the mean change in the 
arimoclomol group was - 2.1. A sample size of 68 subjects per group (136 total)  will 
provide 80% power to detect a treatment group difference in mean response of 1.4 points, 
using a two- sample t -test and a 5% significance level (two- tailed). To account for an 
anticipated 10% drop- out rate, the sample size will be inflated to 75 participants per group 
(150 total).  Although this calculation strictly applies only to a trial with 12- month follow -up, 
it will also apply to this trial if, as expected, the magnitude of the treatment effect relative to the magnitude of the standard deviation of the change in IBMFRS score does not diminish over time.  
11.9 Measures to Minimize Bias 
11.9.1 Breaking the Study Blind/ Participant  Code  
Each site will receive documentation to break the randomization code if needed. The site investigators will not have access to the randomization codes. The investigator or 
pharmacist at the site will have access to the unblinded information for the double- blind 
treatment for each subject via code envelopes.  
The investigator may only break the code for a subject if knowledge of the IMP is necessary to provide optimal treatment to the subject in an emergency situation. If possible, the investigator should consult the Medical Monitor before breaking the code. The investigator must record the date, time, and reason for breaking the code on the code 
envelope and sign it. The subject must be immediately withdrawn from IMP and followed up according to S ection 6.5.   
11.9.2 Unblinding for Data Monitoring Committe e 
Periodic safety review by the Data Monitoring Committee will be facilitated by an unblinded statistician from Premier  not otherwise involved in the study.  The sponsor and 
all other  study personnel will remain blinded. S afety reports will be reviewed by the DMC 
in a closed session. If the recommendation by the DMC is to continue the study, the detailed results of the safety review will not be conveyed to the sponsor until the end of 
the study. In the event that the DMC recommends stopping the study, communications between the DMC and the sponsor  will be strictly limited to a small number of designated 
sponsor representatives. The sponsor will share DMC recommendations with the 
Steering Committee  promptly . The details of the DMC process, including communications 
with the sponsor, will be detailed in the DMC charter and the statistical analysis plan.  
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 78 
08 JU
N 2020 12 SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS 
A CRF is required and should be completed for each included (consented) patient. The 
Investigator will be responsible for the accuracy of the data entered into the CRF. All data 
must be entered in English and must be completed by designated study personnel. The completed CRFs must be reviewed, and electronically signed/dated by the Investigator in 
a timely fashion. If a change is made on any of the eForms after the Investigator has signed that eForm, the Investigator must re -sign the CRF. Relevant completed eForms 
must be available for review at each scheduled monitoring visit.  
The Investigator will allow designated sponsor  representatives and regulatory bodies to 
have direct access to the source documents to verify the data reported in the CRFs.  
Source documents (e.g., medical records, raw data collection forms, pharmacy 
dispensing records, recorded data from automated instruments, laboratory data) are the originals of any documents used by the Investigator or hospital/institution that allow verification of the existence of the patient and substantiate the integrity of the data collected during the trial. Source documents should be available to support all the data recorded in the CRF. The Investigator will prepare and maintain adequate and accurate source documents. These documents are designed to record all observations and other pertinent data for each patient included in this clinical trial.  
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 79 
08 JU
N 2020 13 QUALITY ASSURANCE AND QUALITY CONTROL  
An independent audit of the study may be conducted during the study or after completion. 
The audit may be conducted by either Orphazyme or an independent auditor or a 
regulatory authority.  
13.1 Quality Control 
Quality Control (QC) is defined as the operational techniques and activities undertaken within the QA system to verify that the requirements for quality of the trial -related activities 
have been fulfilled. QC should be applied to each stage of data handling to ensure that all data are reliable and have been processed correctly.  
13.2 Quality Assurance 
Quality Assurance (QA) is defined as the planned and systematic actions that are 
established to ensure that the trial is performed and the data are generated, doc umented 
(recorded) and reported in compliance with GCP and the applicable regulatory requirements.  
13.3 Audit 
The Investigator will permit an audit mandated by the Sponsor after reasonable notice. The purpose of an audit is to confirm that the study is conducted as per protocol, GCP and applicable regulatory requirements, that the rights and well -being of patients enrolled 
have been protected and that all data relevant for the evaluation of the IMP have been captured, processed and reported in compliance with the planned arrangements. The Investigator will permit direct access to all study documents, IMP accountability records, medical records and source data. The Investigator and his/her study team will also be available for discussion regarding study progress  and procedures during the audit (both 
during the audit and at the end of the audit for an “exit” discussion).  
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 80 
08 JU
N 2020 14 ETHICS/PROTECTION OF HUMAN SUBJECTS 
14.1 Institutional Review Board 
It is the responsibility of the local site Investigator to obtain approval of the trial 
protocol/amendments from the IEC/IRB. Prior to the initiation of the study, each site Investigator will submit the following documents to the appropriate IECs/IRBs for approval:  
•The study protocol and any amendments;
•The IB;
•Details of any compensation to patients ;
•The current curriculum vitae of the Principal Investigator;
•Any other requested document(s).
A copy of the approval will be sent to Premier Research along with all other correspondence with the IEC/IRB, including the submission documents. The Investigator should file all correspondence with the IEC/IRB in the Investigator site file.  
The study will not start and no subject may undergo any procedure not part of routine care for the subject’s condition until approval of the protocol and the consent form  has 
been obtained from the appropriate IEC/IRB. The letter of approval should be dated, and should specify the protocol number and date of the protocol or amendment which was 
reviewed and approved. It should also specify the date the ICF was reviewed and 
approved.  
A dated list of the voting members of the IEC/IRB who were present when the protocol was reviewed and approved, including their titles/occupations and institutional affiliations 
should be provided where possible by the Investigator to Premier Research prior to study 
initiation. The Investigator will make all attempts to ensure that the IEC/IRB is constituted and operates in accordance with the ICH -GCP and any local regulations.  
The Investigator will submit any protocol amendments to the IEC/IRB (and other local authorities, according to local regulations) prior to implementation.  
The Investigator will submit required progress reports to the IEC/IRB that approved the protocol at least annually, as well as report any SAEs, life- threatening problems or deaths, 
to comply with ICH- GCP. The Investigator must inform the IEC/IRB of the termination of 
the study.   
14.2 Regulatory Body Approval  
The study will not be started until the sponsor  has received approval from relevant 
regulatory bodies. The sponsor  will provide the Investigator with a copy of the relevant 
document .  
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 81 
08 JU
N 2020 14.3 Informed Consent a nd Screening Data 
Any changes requested by the IEC/IRB must be approved by the IEC/ IRB prior to the 
documents being used. A copy of the final, IEC/IRB -approved consent form must be 
submitted to Premier Research prior to initiation of this study.  
Written informed consent will be obtained from each patient prior to inclusion in the trial, 
and prior to any study -related assessments are performed.  
14.3.1 Confidentiality  
Participant confidentiality and privacy is strictly held in trust by the participating investigators, their staff, and the sponsor and their representatives. This confidentiality is extended to cover testing of biological samples and genetic tests in addition to the clinical information relating to participants. Therefore, the study protocol, documentation, data, and all other information generated will be held in strict confidence. No information concerning the study or the data will be released to any unauthorized third party without prior written approval of the sponsor.  
All research activities will be conducted in as private a setting as possible.  
The study monitor, other authorized representatives of the sponsor, representatives of the IRB, regulatory agencies, or companies supplying study product may inspect all documents and records required to be maintained by the investigator, including, but not limited to, medical records (office, clinic, or hospital) and pharmacy records for the participants in this study. The clinical study sites will permit access to such records.  
The study participant’s contact information will be securely stored at each clinical site for internal use during the study. At the end of the study, all records will continue to be kept in a secure location for as long a period as dictated by the reviewing IRB, institutional policies, or sponsor requirements.  
Study participant research data for purposes of statistical analysis and scientific reporting will be transmitted to and stored at Premier Research and the University of Rochester . 
This will not include the participant’s contact or identifying information. Rather, individual participants and their research data will be identified by a unique study identification number. The study data entry and study management systems used by clinical sites and by Premier Research and University of Rochester  staff will be secured and password 
protected. At the end of the study, all study databases will be de- identified and archived. 
The Investigator  must ensure that the patients’ anonymity will be maintained. 
The Investigator should keep a separate log (Patient Master List) of patient’s codes (assigned patient number), names, addresses, telephone numbers and hospital numbers (if applicable). Documents not for submission to the sponsor (e.g. signed informed consent forms) should be maintained by the Investigator in strict confidence.  
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 82 
08 JU
N 2020 14.3.2 Staff Information and Responsibilities  
It is the responsibility of the local site Investigator to ensure that all personnel involved in 
the study are fully informed of all relevant aspects of the study, including detailed knowledge of and training in all procedures to be followed to allow collection of accurate, consistent, complete and reliable data.  
The local site Investigator will provide a list of delegated responsibility to Premier 
Research, detailing the various study tasks to be performed by each member of his/her study staff. Each staff member should sign in agreement to their performing each of the tasks delegated to them on the list. The local site Investigator  should ensure that the staff 
have the required knowledge and training for the tasks delegated to them.  
14.3.3 Essential Document Retention 
All clinical information shall be r ecorded, handled and stored in such a way that it can be 
accurately reported, interpreted and verified, while ensuring confidentiality of the trial patients’ personal data. Documents that enable both the conduct of the clinical trial and the quality of the data produced to be evaluated; and show whether the trial is, or has 
been, conducted in accordance with ICH -GCP and applicable regulatory requirements 
are considered essential documents.  
The Investigator will retain copies of all the essential documents (as defined by ICH -GCP) 
until at least 2 years after the last approval of a marketing application in an ICH region, and until there are no pending or contemplated marketing applications in an ICH region, or at least 2 years have elapsed since the formal discontinuation of clinical development of the IMP. The period of document retention is, however, also dependent on the applicable regulatory requirements (e.g. EEC Directive 91/507 requires retention of 
patient codes for at least 15 years after the completion or discontinuation of a trial and 
retention of hospital records and other source data for the maximum time permitted by the institution where the study takes place). The Investigator should take measures to prevent accidental or premature destruction of these documents.  
The essential documents include: the signed protocol, copies of the completed CRFs, hospital records and other source documents, IEC/IRB approval and all related correspondence, including approved documents, and all other documentation included in the Investigator site file .  
The Investigator will inform the Sponsor of the storage location of these essential documents and must contact the Sponsor before disposing of any. If the Investigator wishes to assign the files to someone else (e.g. if he/she retires) or to remove them to another location, the Sponsor Project Manager should be consulted about this change.  
The Sponsor will inform the Investigator in writing when these documents no longer need 
to be retained.  
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 83 
08 JU
N 2020 14.4 Data Handling and Record K eeping 
14.4.1 Data Collection and Management Responsibilities 
Data will be collected and entered into an electronic data capture system (Datalabs) 
provided by Premier Research Inc.  Datalab s is a web -based 21 CRF Part 11- compliant 
database system which will be customized specifically for this clinical trial. Premier 
Research will be responsible for managing the database. Drug dispensing logs will be 
kept to record the total amount of medication received from and returned to the site. Completed informed consent forms from each subject will be available in the subject’s file and verified for proper documentation.  
Data collection is the responsibility of the clinical trial staff at the site under the supervision 
of the local site PI. The investigator is responsible for ensuring the accuracy, 
completeness, legibility, and the timeliness of the data reported.  
All source documents should be completed in a neat, legible manner to ensure accurate interpretation of data. Black or blue ink is required to ensure clarity of reproduced copies. When making changes or corrections, cross out the original entry with a single line, and initial and date the change. DO NOT ERASE, OVERWRITE, OR USE CORRECTION FLUID OR TAPE ON THE ORIGINAL.  
Sourc e documents will be stored at each of the clinical sites in double locked storage.  
Data reported in the CRF derived from source docum ents should be consistent with the 
source do cuments or the discrepancies should be explained and captured in a progress 
note and maintained in the participant’s official study record.  
Clinical data (including AEs, concomitant medications, and expected adverse reactions  
data) and clinical laboratory data will be entered into Datalabs. The data system includes 
password protection and internal quality checks, such as automatic range checks, to 
identify data that appear inconsistent, incomplete, or inaccurate. Clinical data will be entered directly from the source documents.   
The site investigators will be responsible for insuring that all blank data spaces on each CRF are filled in.  The Premier DM group will notify each investigator of any missing or 
inconsistent data.  All completed CRFs are to be reviewed by the site investigator.   
14.4.2 Protocol Adherence  
The study PI will work closely with PI s at all other sites to ensure adherence of the protocol 
by the study sites and study data integrity. The Sponsor PI will be responsible for 
communicating with all sites to ensure smooth conduct of the study and prompt data  
submission. The PI  will coordinate e- mail and conference call communications and work 
with the data coordinator to prepare monthly reports from each site indicating the status of the study and problems that might arise. Serious adverse events will be reported immediately to the Sponsor PI and reviewed promptly by the medical  safety monitor.  
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 84 
08 JU
N 2020 Based upon our previous experience in managing multicenter studies of neuromuscular 
disorders at KUMC, we will again assemble a communications and computing infrastructure and technical staff to ensure the success of this study. We will use strategies for intra- and inter -site communication, data entry, storage, management, and 
analysis similar to those we have previously used and currently use. We will have several ways  to ensure adequate communication between the data center and the individual 
clinical sites. Telephone, fax, and electronic mail will be the primary modes of inter - and 
intra-site communication for investigators and study staff. The existing infrastructure at 
each site includes sophisticated telephone networks, voice messaging systems, fax machines and Ethernet connections to the Internet to support this strategy. All study computers at the data center and each of the clinical sites will be password protect ed, 
and kept in locked offices. The evaluators performing the monthly studies will complete a CRF after each visit. The PI/study coordinator will be responsible for dispensing and 
accounting for all study medication. The PI  at each study site is responsible for all aspects 
of the study at the site. The investigator agrees to cooperate fully with monitors.  
14.4.3 Data Storage and Backup 
Data backup, restore and security will be handled as per Premier Research’s Data Management Plan  
14.4.4 Study Records Retention 
Study records must be retained for 5 years after the close of the study or until the drug is approved for two years by the FDA.  
14.4.5 Protocol Deviations  
The trial must be conducted in accordance with: 
•The protocol;
•Applicable regulatory requirement(s) or conditions linked to the approval(s) of thestudy;
•Applicable IEC/IRB requirement or conditions linked to the approval(s) of the study;
•Any particulars or documents, other than the protocol, accompanying the regulatoryor IEC/IRB request or that application.
Protocol waivers will not be granted. Any amendment(s) to the protocol must be approved by both Orphazyme A /S and the IEC/IRB which granted the original approval of the study 
prior to their implementation (unless only logistical or administrative aspects of the trial are involved). All substantial amendments to the protocol must be approved by the applicable regulatory bodies prior to their implementation.  
However, in the event of any medical emergency, the Investigator is free to institute any medical procedure he/she deems appropriate. Such events and procedures must be promptly reported to the Orphazyme A /S representatives.  
CONFIDENTIAL
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 86 
08 JU
N 2020 15 STUDY ADMINISTRATION 
15.1 Study Leadership 
A Scientific Steering Committee will govern the conduct of the study  and provide scientific 
direction. The Steering Committee composition is given in protocol section 2. The 
Steering Committee will meet  and act  according to the Steering Committee Charter . 
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 87 
08 JU
N 2020 16 CONFLICT OF INTEREST POLICY  
Any actual conflict of interest of persons who have a role in the design, conduct, analysis, 
publication or any aspect of this trial will be disclosed and managed. Furthermore, 
persons who hav e a perceived conflict of interest will be required to have such conflicts 
managed in a way that is appropriate to their participation in the trial. The study leadership in conjunction with the FDA -OPD has established policies and procedures for all study 
group members to disclose all conflicts of interest and will establish a mechanism for the 
management of all reported dualities of interest.  
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 88 
08 JU
N 2020 17 CORONAVIRUS (COVID) OPERATIONAL CHANGES 
The
 document (COVID-19) Addendum 1.0 dated 24- Mar-2020 shall remain in ef fect with this 
Clinical Trial Protocol. The Addendum to the Clinical Trial Protocol is designed to mitigate the 
operational impact resulting from COVID -19, and shall only be applied as an interim solution 
during the period that normal Clinical Trial Protoc ol logistics cannot be adhered to. Once 
containment measures have ceased and operations return to normal on both a site and subject level, procedures will resume as per the site’s currently approved Clinical Trial Protocol.  
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 89 
08 JU
N 2020 18 LITERATURE REFERENCES 
1.Rose MR,  ENMC IBM working group. 188th ENMC International Workshop:
Inclusion Body Myositis, 2- 4 December 2011, Naarden, The Netherlands.
Neuromuscular disorders: NMD. 2013 Dec; 23(12):1044- 1055.
2.Kal
mar B, Greensmith L. Activation of the heat shock response in a primary cellular
model of motoneuron neurodegeneration- evidence for neuroprotective and
neurotoxic effects. Cell Mol Biol Lett 2009; 14(2): 319- 335.
3.Douglas PM, Cyr DM. Interplay between protein homeostasis networks in protein
aggregation and proteotoxicity. Biopolymers 2010; 93(3): 229- 236.
4.Kopito RR. Aggresomes, inclusion bodies and protein aggregation. Trends CellBiol. 2000; 10(12): 524- 530.
5.Brown IR. Heat shock proteins and protection of the nervous system. Ann N YAcad Sci 2007; 1113: 147- 158.
6.Ahmed M,  Machado PM, Miller A, Spicer C, Herbelin L, He J, Noel J, Wang Y,
McVey AL, Pasnoor M, Gallagher P, Statland J, Lu C -H, Kalmar B, Brady S, Sethi
H, Samandouras G, Parton M, Holton J, Weston A, Collinson L, Taylor JP, SchiavoG, Hanna MG, Richard J. Barohn RJ, Dimachkie MM* & Linda Greensmith.*
Targeting protein homeostasis in Sporadic Inclusion Body Myositis. Sci Transl Med2016; 23 (8):331ra41.doi:10.1126/scitranslmed.aad4583.
7.Moussa CE, Fu Q, Kumar P, Shtifman A, Lopez JR, Allen PD, et al. Transgenicexpression of beta- APP in fast -twitch skeletal muscle leads to calcium
dyshomeostasis and IBM like pathology. FASEB J. 2006; 20(12): 2165- 2167.
8.Machado P, Dimachkie MM, Barohn RJ. Sporadic Inclusion Body Myositis: newinsights and potential therapy. Curr Opin Neurol 2014; Oct 27:591- 8.
9.Machado, P, Ahmed M, Brady S, Gang Q, Healy E, et al. Ongoing developmentsin sporadic inclusion body myositis. Curr Rheumatol Rep. 2014; 16:477.
10. Am
ato AA, Barohn RJ. Evaluation and treatment of inflammatory myopathies.
JNNP. 2009;80(10):1060- 1068
11. Enge
l WK, and Askanas, V. Inclusion- body myositis: Clinical, diagnostic, and
pathologic aspects. Neurology. 2006; 66(Suppl 1): S20- S29
12. Am
ato AA, Barohn RJ. Idiopathic inflammatory myopathies. Neurol. Clin. N. Amer.
1997; 15: 615- 648.
13. Am
ato AA, Gronseth GS, Jackson CE, Wolf GI, Katz JS, Bryan WW, Barohn RJ.
Inclusion body myositis —clinical and pathological boundaries. Ann. Neurol. 1996;
40: 581- 586.
14. Gr
iggs RC, Askanas V, DiMauro S, Engel A, Karpati G, Mendell JR, et al . Inclusion
body myositis and myopathies. Annals of Neurology 1995; 38: 705- 713.
15. Rabi
 Tawil, MD, and Robert C. Griggs, MD. Inclusion body myositis.  Curr Opin
Rheumatol 2002, 14:653– 657
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 90 
08 JU
N 2020 16. Amato AA, Barohn RJ. Inclusion body myositis: old and new concepts. JN NP
2009;80(10):1186- 93.
17. Di
machkie MM. Idiopathic inflammatory myopathies. J Neuroimmunol.  2011
Feb;231(1- 2):32- 42.
18. Di
machkie MM and Barohn RJ. Inclusion Body Myositis. Curr Neurol Neurosci
Rep.  2013 Jan;13(1):321
19. Di
machkie MM, Barohn RJ. Inclusion body myositis in Neuromuscular Therapy:
From Bench to Bedside. Semin Neurol. 2012Jul;32(3):237- 45.
20. Barohn RJ and Dimachkie MM. Inclusion Body Myositis. Neurol Clin 2014;
Aug;32:629 -646.
21. Invited contribution, Dimachkie MM, Barohn RJ, Idiopathic InflammatoryMyopathies, ABIM Internal Medicine Boards Review, Epub version is also onKindle and Nook, Ragavendra R Baliga Editor, 2012.
22. Mas
talgia FL, Garlepp MJ, Phillips BA, Zilko PJ. Inflammatory myopathies: clinical,
diagnostic, and therapeutic aspects. Muscle and Nerve. 2003;  27: 407- 425.
23. Phillips BA, Cala LA, Thickbroom GW, Melsom A, Zilko PJ, Mastalgia FL. Patternsof muscle involvement in inclusion body myositis: clinical and magnetic resonanceimaging study. Muscle and Nerve. 2001; 24: 1526- 1534.
24. Dimachkie MM, Barohn RJ. Idiopathic inflammatory myopathies. FrontNeurol/Neurosci. 2009;26:126- 46.
25. Griggs  RC. The current status of treatment for inclusion- body myositis. Neurology.
2006; 66(Suppl 1): S30- S32.
26. Rose MR, McDermott, MP, Thornton CA, Palenski C, Martens WB, Griggs RC. A
prospective natural history study of inclusion body myositis: implications for clinical
trials. Neurology 2001;57:548- 550.
27. Muscle Study Group. Randomized pilot trial of betaINF1a (Avonex) in patients withinclusion body myositis. Neurology 2001;57:1566- 1570.
28. Muscle Study Group. Randomized pilot trial of high- dose betaINF- 1a in patients
with inclusion body myositis. Neurology 2004;63:718- 720.
29. Benveniste O, Guiguet M, Freebody J, et al. Long- term observational study of
sporadic inclusion body myositis. Brain 2011;134 (Pt 11):3176– 3184.
30. Estephan B,  Barohn RJ, Dimachkie MM et al. Sporadic IBM: a Case Cohort.Journal of Clinical Neuromuscular Disease. 2011; 12(3):18- 19
31. Salajegheh M, Pinkus JL, Taylor JP, et al. Sarcoplasmic redistribution of nuclearTDP- 43 in inclusion body myositis. Muscle Nerve 2009;40(1):19– 31
32. Subour
g O, Wanschitz J, Maisonobe T, et al. Diagnositic value of markers of
muscule degeneration in sporadic inclusion body myositis. Acta Myol. 201130;103- 8.
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 91 
08 JU
N 2020 33. Askanas V, Engel WK. Molecular  Pathology and Pathogenesis of Inclusion- Body
Myositis. Microscopy Research and Technique. 2005; 67: 114- 120.
34. Askanas V, Engel WK, Nogalska A. Sporadic inclusion- body myositis: A
degenerative muscle disease associated with aging, impaired muscle protein
homeostasis and abnormal mitophagy. Biochim Biophys Acta. 2015; Apr1852(4):633- 43.
35. As
kanas V, Engel WK. Inclusion- bodymyositis: amyodegenerative conformational
disorder associated with Abeta, protein misfolding, and proteasome inhibition.Neurology 2006;66(2, Suppl 1):S39– S48.
36. Oz
turk A, McFerrin J, Engel WK, Askanas V. HSP70 chaperone machinery in
sporadic inclusion- body myositis muscle fibers. Neurology. 2004; 62: 168.
37. Frat
ta P, Engel WK, McFerrin J, Davies KJA, Lin SW, Askanas V. Proteosome
inhibition and aggresome formation in sporadic inclusion- body myositis and in
amyloid -B precursor protein- overexpressing cultured human muscle fibers. Am J
Pathology. 2005; 167(2): 517- 526.
38. Enge
l WK, and Askanas, V. Inclusion- body myositis: Clinical, diagnostic, and
pathologic aspects. Neurology. 2006; 66(Suppl 1): S20- S29.
39. Forl
oni G, Terreni L, Bertani I et al. Protein misfolding in Alzheimer's and
Parkinson's disease: genetics and molecular mechanisms. Neurobiol Aging.2002;23:957- 976.
40. Har
tl F, Hayer -Hartl M. Molecular chaperones in the cytosol: from nacent chain to
folded protein. Science. 2002;295:1852- 1858.
41. Sher
man MY, Goldberg AL. Cellular defenses against unfolded proteins: a cell
biologist thinks about neurodegenerative diseases. Neuron 2001; 29(1): 15- 32.
42. Kier
an D, Kalmar B, Dick JR et al. Treatment with Arimoclomol, a coinducer of heat
shock proteins, delays disease progression in ALS mice. Nat Med. 2004;10:402-405.
43. Mor
row JM, Ramdharry GR, Machado P, Burns T, Amato A, Barohn R, Phillips L,
Seyedsadjadi R, Joshi A, Dimachkie M, Gwathmey K, Herbelin L, Solorzano G,Hanna M. RASCH ANALYSIS OF THE IBMFRS. Muscle & Nerve. 2013; 48 (Supp1), S2 -3.
44. Jac
kson CE, Barohn RJ, Gronseth G, Pandya S, Herbelin L; Muscle Study Group.
Inclusion body myositis functional rating scale: a reliable and valid measure ofdisease severity. Muscle Nerve.  2008 A pr;37(4):473-6
45. Rohn TT.
 Caspase- cleaved TAR DNA -binding protein- 43 is a major pathological
finding in Alzheimer's disease. Brain Res 2008; 1228: 189- 198.
46. Kuner
 P, Hertel C. NGF induces apoptosis in a human neuroblastoma cell line
expressing the neurotrophin receptor p75NTR. J Neurosci Res 1998; 54(4): 465-474.
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 92 
08 JU
N 2020 47. Feinstein DL, Galea E, Aquino DA, Li GC, Xu H, Reis DJ. Heat shock protein 70
suppresses astroglial -inducible nitric -oxide synthase expression by decreasing
NFkappaB activation. J Biol Chem  1996; 271(30): 17724- 17732.
48. Am
ato AA, Barohn RJ, Jackson CE, Pappert EJ, Sahenk Z, Kissel JT. Inclusion
body myositis: treatment with intravenous immunoglobulin. Neurol 1994; 44(8):1516- 1518.
49. Dal
akas MC, Koffman B, Fujii M, Spector S, Sivakumar K, Cupler  E. A controlled
study of intravenous immunoglobulin combined with prednisone in the treatmentof IBM. Neurology 2001;56:323- 7.
50. Br
eithaupt M, Schmidt J. Update on treatment of inclusion body myositis. Curr
Rheumatol Rep 2013; 15(5): 329.
51. Barohn RJ, Jackson C, Pandya S, Gronseth G, Herbelin L, The Muscle StudyGroup (MSG).   Inclusion body myositis functional rating scale.  Neurology 2007;68
(Suppl. 1):A361.
52. Lowes
 LP, Alfano L, Viollet L, Rosales XQ, Sahenk Z, Kaspar BK, Clark KR,
Flanigan KM, Mendell JR, M cDermott MP. Knee extensor strength exhibits
potential to predict function in sporadic inclusion- body myositis.Muscle Nerve.
2012 Feb;45(2):163- 8.
53. Sal
ajegheh M, Lam T, Greenberg SA. Autoantibodies against a 43 KDa muscle
protein in inclusion body myositis.  PLoS One. 2011; 6(5):e20266
54. Benjamin Larman H, Salajegheh M, Nazareno R, Lam T, Sauld J, Steen H, et al.Cytosolic 5' -nucleotidase 1A autoimmunity in sporadic inclusion body myositis.
Ann Neurol. 2013 Mar; 73(3):408- 418.
55. Pl
uk H, van Hoeve BJ, van Dooren SH, Stammen- Vogelzangs J, van der Heijden
A, Schelhaas HJ, et al. Autoantibodies to cytosolic 5'- nucleotidase 1A in inclusion
body myositis. Ann Neurol. 2013 Mar; 73(3):397- 407].
56. Mus
cle Study Group. A randomized pilot trial of etanercept in dermatomyosisits.
Ann Neurol 2011. Sep;70(3):427- 436.
57. Fries JF, Spitz PW, et al. Measurement of patient outcome in arthritis. Arthritis
Rheum 1980;23(2): 137- 45.
58. Fri
es JF, Spitz PW, et al. The dimensions of health outcomes: the healt h
assessment questionnaire, disability and pain scales. J Rheumatol 1982;9(5): 789-93.
59. Mol
enberghs G, Thijs H, Jansen I, Beunckens C, Kenward MG, Mallincdrodt C,
Carroll RJ. Analyzing incomplete longitudinal clinical trial data. Biostatistics 2004;5:445-4 64.
60. Cox FM, Titulaer MJ, Sont JK, et al. A 12- year follow -up in sporadic inclusion body
myositis: An end stage with major disabilities. Brain 2011;134(11):3167– 75.
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 93 
08 JU
N 2020 61. Price MA, Barghout V, Benveniste O, et al. Mortality and causes of death in
patients with sporadic inclusion body myositis: Survey study based on the clinicalexperience of specialists in Australia, Europe and the USA. J Neuromuscul Dis.2016;Mar 3;3(1):67- 75.
62. Lilleker JB, Rietveld A, Pye SR, et al.Cytosolic 5' -nucleotidase 1A autoantibody
profil e and clinical characteristics in inclusion body myositis. Ann Rheum Dis.
2017;Jan 25. pii: annrheumdis -2016- 210282. doi: 10.1136/annrheumdis -2016 -
210282 [Epub ahead of print].
63. Carpenter JR, Roger JH, Kenward MG.  Analysis of longitudinal trials with protocoldeviation: a framework for relevant, accessible assumptions and inference viamultiple imputation.  J Biopharm Statist 2013; 23:1352- 1371.
64. FDA Guidance for Industry on Drug- Induced Liver Injury: Premarketing Clinical
Evaluation, July 2009
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 94 
08 JU
N 2020 APPENDIX  1: EUROPEAN NEUROMUSCULAR CENTRE INCLUSION 
European Neuromuscular Centre Inclusion Body Myositis research diagnostic criteria 
2011  
Diagnostic sub- group Clinico -
pathologically 
defined IBM  Clinically  
defined IBM  Probable  
IBM 
Clinical features 
Duration of weakness > 12 months  X X X 
Age at onset > 45 years  X X X 
Creatine kinase ≤ 15x ULN  X X X 
FF weakness > SA weakness 
AND/OR KE weakness ≥ HF 
weakness  X - - 
FF weakness > SA weakness  
 AND KE weakness ≥ HF 
weakness  - X - 
FF weakness > SA weakness  
 OR KE weakness ≥ HF 
weakness  - - X 
Pathological features  
Endomysial inflammatory infiltrate  X 
≥1, but not all 
of the 4 
pathological 
features  ≥1, but not all 
of the 4 
pathological 
features  Rimmed vacuoles  X 
Protein accumulation* or 15-18nm filaments  X 
Up-regulation of MHC Class I  - 
*Demonstration of amyloid or other protein accumulation by established methods (e.g.for amyloid Congo red, crystal violet, thioflavin T/S, for other proteins p62, SMI -31, TDP -
43). FF, Finger flexion; HF, Hip flexion; KE, Knee extension; SA, Shoulder abduction;MHC Class I, Major histocompatibility complex class I; ULN = Upper limit of normal.
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclom
ol 
Module    5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM  
Page 95 
08 JU
N 2020 APPENDIX 2: IBM FUNCTIONAL RATING SCALE  
1. SWALLOWING
4 Normal
3 E
arly eating
problems – 
occasional 
choking  
 2 Dietary 
consistency 
changes  
 1 Frequent choking  
 0 Needs tube 
feeding  
2. HANDWRITING
(with dominant
hand prior to IBMonset)
4 Normal3 Slow or sloppy; all
words are legible
2 Not all  words are
legible
1 Able to grip pen
but unable to write  
 0 Unable to grip 
pen 
3. CUTTING FOOD
AND HANDLINGUTENSILS
4 Normal3 Somewhat slow
and clumsy, but no help needed  
 2 Can cut most 
foods, although clumsy & slow; some help needed  
 1 Food must be cut 
by someone but can still feed slowly  
 0 Needs to be fed  4. FINE MOTOR TASKS
(opening doors, usingkeys, picking up smallobjects)
 4 Independent  
 3 Slow or c lumsy in  
completing task  
 2 Independent but requires 
modified techniques or assistive devices  
 1 Frequently requires 
assistance from caregiver  
 0 Unable  
5. DRESSING
4 Normal3 Independent but with
inc
reased effort or 
decreased efficiency  
 2 Independent but requires 
assistive devices or modified techniques (Velcro snaps, shirts without buttons, etc.)  
 1 Requires assistance from 
caregiver for some clothing items  
 0 Total dependence  
6. HYGIENE (Bathing and
toileting)
 4 Normal  
 3 Independent but with 
increased effort or decreased activity  
 2 Independent but requires 
use of assistive devices (shower chair, raised toilet seat, etc.)  
 1 Requires occasional 
assistance from caregiver  
 0 Completely dependent  7. TURNING IN BED &
ADJUSTING COVERS
4 Normal
3
 Somewhat slow & clumsy
but no help needed
2 Can turn alone or adjust
sheets but with great difficulty  
 1 Can initiate but not turn 
or adjust sheets alone 
 0 Unable or requires total 
assistance 
8. SIT TO STAND
4 Independent (without use
of arms)
3 Performs with substitute
motions (leaning forward, rocking) but without use of arms)  
 2 Requires use of arms  
 1 Requires assistance from 
device/person 
 0 Unable to stand 
9. WALKING
4 Normal3 Slow or mild
unsteadiness
2 Intermittent use of
assistive device (AFO, cane, walker)  
 1 Dependent on assistive 
device  
 0 Wheelchair dependent  
10. CLIMBING STAIRS
4 normal3 Slow with hesitation or
increased effort; uses handrail intermittently  
  2 Dependent on handrail  
  1 Dependent on handrail 
and additional support (cane or person)  
  0 Cannot climb stairs  
CONFIDENTIAL
, M.D. (KUMC) 
Arimoclomol 
Module 5.3.5.1: Phase 2/3 Study of Arimoclomol in IBM 
APPENDIX 3: - SUB-STUDY 
This was an exploratory sub-study and the details are not relevant for the primary or
secondary endpoints and therefore not included here.
Page 96 
08JUN2020 CONFIDENTIAL
Protocol number: IBM4809  Date: 23-Sep-2020  Version: Fin al 1.0  
Addendum  1.0 to 
Clinical Trial Protocol v 9.0 dated 08-Jun-2020 
Phase 2/3 Study of Arimoclomol in Inclusion Body 
Myositis (IBM) 
A Randomized, Double-blind, Placebo-Controlled Trial
Sponsor: Orphazyme A/S, Ole Maaløes Vej 3, DK-2200 Copenhagen 
N, Denmark 
International Coordinating investigator: , MD, Professor of 
Neurology 
Protocol number: IBM4809 
EudraCT No.: 2017-004903-33 
Study Registry ID: [REMOVED]
Trial product name:  Arimoclomol Capsules 
Date of Addendum: 23-Sep-2020 
The trial will be conducted according to 
the protocol and in compliance with Good Clinical Practice (GCP), with the 
Declaration of Helsinki and with other applicable regulatory requirements 
Orphazyme A/S - Strictly Confidential 
(IB, CYP2D6 DDI) Addendum 1.0 to CTPv9.0, dated 23-Sep-2020 
Page 1 of 6 This document contains information which is the property of KemPharm Denmark A/S and 
is provided here as part of the results registration on clinicaltrials.gov. It is understood that 
this information cannot and will not be disclosed to others without written approval from 
KemPharm Denmark A/S.

Protocol number: IBM4809  Date: 23-Sep-2020  Version: Fin al 1.0  
Orphazyme A/S - Strictly Confidential  
(IB, CYP2D6 DDI ) Addendum 1.0 to CTPv 9.0, dated 23-Sep-2020  
Page 2 of 6 
Contents  
Acknowledgement Statement Investigators  ................................ .....................  Error! Bookmark not defined.
Justification for Addendum  ................................ ................................ ................................ ............................  3
Modifica tion to the Clinical Trial Protocol due to update of Investigator Brochure version 4.0 dated 
15-SEP-2020  ................................ ................................ ................................ ................................ .....................  4
Protocol number: IBM4809  Date: 23-Sep-2020  Version: Fin al 1.0  
Orphazyme A/S - Strictly Confidential  
(IB, CYP2D6 DDI ) Addendum 1.0 to CTPv 9.0, dated 23-Sep-2020  
Page 3 of 6 
Justification for Addendum  
Results from an in vitro study showed that arimoclomol is a direct inhibitor of CYP2D6  with an IC50 of190 
µM which is > 25 times higher than clinical exposure  (Cmax ) 
The investigator’s Brochure was previously updated with these findings and correspondingly the Clinical 
trial Protocol (CTP) was updated to indicate that concomitant treatment with CYP2D6 substrates should be 
done with caution (since their exposure could increase as a result of their metabolism being inhib ited).  
By using mechanistic static model ling, instead of basic equations, it has since been evaluated  that the in vitro  
CYP2D6  inhibition is not clinically relevant . These findings have been included in the annual update of the 
Investigator’s Brochure  and the updated guidance on use of concomitant medications are included in this 
CTP addendum.  
The changes described are done to ensure continued safety and well -being of the subjects and the integrity of 
the clinical trial. A sponso r risk assessment  has concluded that the change s in this addendum are no t likely to 
affect the safety and well -being of the participants or the scientific value of the trial. Therefore, t he Sponsor 
confirms that the benefit -risk evaluation for arimoclomol in IBM  is not changed.  